Variant Annotation ID	Variant/Haplotypes	Drug(s)	Phenotype Category	Significance	Sentence	Allele Of Frequency In Cases	Allele Of Frequency In Controls	P Value	Ratio Stat Type	Ratio Stat	Confidence Interval Start	Confidence Interval Stop
1451307925	rs9839376	ritodrine	Efficacy	yes	Genotype CC is associated with decreased response to ritodrine as compared to genotypes CT + TT.			< 0.05	HR	2.68	1.16	6.2
1451307920	rs7624046	ritodrine	Efficacy	yes	Genotype TT is associated with decreased response to ritodrine as compared to genotypes CC + CT.			< 0.05	HR	2.06	1.14	3.73
1451339660	rs10011796	allopurinol	Efficacy	no	Allele T is not associated with decreased response to allopurinol in people with Gout as compared to allele C.	T	T	= 0.017	OR	1.55	1.08	2.23
1451339660	rs10011796	allopurinol	Efficacy	no	Allele T is not associated with decreased response to allopurinol in people with Gout as compared to allele C.	T	T	= 0.59	OR	1.12	0.73	1.73
1451339660	rs10011796	allopurinol	Efficacy	no	Allele T is not associated with decreased response to allopurinol in people with Gout as compared to allele C.			= 0.689	OR	1.063	0.789	1.431
1451339600	rs2231142	allopurinol	Efficacy	yes	Allele T is associated with decreased response to allopurinol in people with Gout as compared to allele G.	T	T	= 0.00024	OR	2.51	1.56	4.18
1451339600	rs2231142	allopurinol	Efficacy	yes	Allele T is associated with decreased response to allopurinol in people with Gout as compared to allele G.	T	T	= 0.00073	OR	2.35	1.44	3.91
1451339600	rs2231142	allopurinol	Efficacy	yes	Allele T is associated with decreased response to allopurinol in people with Gout as compared to allele G.			< 0.001	OR	2.424	1.71	3.436
1451359472	rs1611114	methadone	Dosage	no	Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele C.	C		= 0.841	OR	0.976	0.774	1.233
1451359106	rs10064525	heroin	Efficacy	no	Allele G is not associated with response to heroin as compared to allele T.	G		= 0.286	OR	0.734	0.416	1.297
1451359340	rs10064525	heroin	Dosage	no	Allele G is not associated with dose of heroin in people with Heroin Dependence as compared to allele T.	G		= 0.482	OR	0.856	0.555	1.321
1451359100	rs1611114	heroin	Efficacy	no	Allele T is not associated with response to heroin as compared to allele C.	C		= 0.485	OR	1.092	0.852	1.4
1451359274	rs1611114	heroin	Dosage	no	Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele C.	C		= 0.545	OR	1.066	0.867	1.309
1451359481	rs10064525	methadone	Dosage	no	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele T.	G		= 0.210	OR	1.363	0.838	2.215
1451359140	rs27072	heroin	Efficacy	no	Allele T is not associated with response to heroin as compared to allele C.	T		= 0.172	OR	1.206	0.921	1.579
1451359336	rs129882	heroin	Dosage	no	Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele C.	T		= 0.697	OR	0.96	0.782	1.178
1451359149	rs129882	heroin	Efficacy	no	Allele T is not associated with response to heroin as compared to allele C.	T		= 0.797	OR	1.033	0.806	1.323
1451359247	rs3842727	heroin	Efficacy	no	Allele T is not associated with response to heroin as compared to allele G.	G		= 0.956	OR	0.982	0.526	1.835
1451359269	rs5320	heroin	Efficacy	no	Allele A is not associated with response to heroin as compared to allele G.	A		= 0.246	OR	1.216	0.873	1.692
1451359440	rs11575553	heroin	Dosage	no	Allele A is not associated with dose of heroin in people with Heroin Dependence as compared to allele G.	A		= 0.230	OR	0.831	0.614	1.125
1451359160	rs6347	heroin	Efficacy	no	Allele C is not associated with response to heroin as compared to allele T.	C		= 0.696	OR	1.074	0.75	1.539
1451359200	rs12666409	heroin	Efficacy	no	Allele A is not associated with response to heroin as compared to allele T.	A		= 0.801	OR	0.97	0.764	1.231
1451359260	rs11575553	heroin	Efficacy	no	Allele A is not associated with response to heroin as compared to allele G.	A		= 0.724	OR	0.935	0.646	1.354
1451359460	rs129915	heroin	Dosage	no	Allele G is not associated with dose of heroin in people with Heroin Dependence as compared to allele A.	G		= 0.672	OR	1.044	0.857	1.271
1451359252	rs6356	heroin	Efficacy	no	Allele T is not associated with response to heroin as compared to allele C.	T		= 0.974	OR	0.995	0.711	1.391
1451359265	rs129915	heroin	Efficacy	no	Allele G is not associated with response to heroin as compared to allele A.	G		= 0.179	OR	1.178	0.928	1.795
1451359432	rs6356	heroin	Dosage	no	Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele C.	T		= 0.401	OR	0.888	0.673	1.172
1448601898	rs11178998	venlafaxine	Efficacy	no	Allele A is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele G.			= 0.009	OR	1.16	0.64	2.12
1448601887	rs11178997	venlafaxine	Efficacy	no	Allele A is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele T.			= 0.009	OR	1.09	0.63	1.88
1448601874	rs1800532	venlafaxine	Efficacy	no	Allele G is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele T.			= 0.009	OR	0.8	0.57	1.13
1450813798	rs7164594	varenicline	Efficacy	yes	Genotypes CT + TT are associated with increased response to varenicline in people with Tobacco Use Disorder as compared to genotype CC.	T		= 0.0019	OR	1.76	1.23	2.52
1448601868	rs9567746	venlafaxine	Efficacy	no	Allele A is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele G.			= 0.009	OR	1.04	0.69	1.57
1448601857	rs6311	venlafaxine	Efficacy	no	Allele C is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele T.			= 0.009	OR	0.74	0.54	1.03
1448601851	rs2274639	venlafaxine	Efficacy	no	Allele C is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele G.			= 0.009	OR	0.89	0.54	1.46
1448601840	rs6296	venlafaxine	Efficacy	no	Allele C is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele G.			= 0.009	OR	1.05	0.73	1.52
1448601834	rs130058	venlafaxine	Efficacy	no	Allele A is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele T.			= 0.009	OR	1.12	0.77	1.63
1448601828	rs11568817	venlafaxine	Efficacy	no	Allele C is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele A.			= 0.009	OR	0.99	0.71	1.36
1448601816	rs6295	venlafaxine	Efficacy	no	Allele C is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele G.			= 0.009	OR	1.0	0.72	1.4
1448601808	rs25531	venlafaxine	Efficacy	no	Allele C is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele T.			= 0.009	OR	1.23	0.91	1.66
1450813804	rs8109525	bupropion	Efficacy	yes	Genotype GG is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes AA + AG.	G		= 0.0008	OR	1.78	1.27	2.5
1450371553	rs396991	tocilizumab	Efficacy	yes	Genotype AA is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes AC + CC.	A		= 0.027	OR	5.075	1.2	21.33
1451239960	rs2853542	methotrexate	Efficacy	yes	Genotype GG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.	G	G	= 0.02	OR	5.4	1.0	21.1
1450371578	rs1801274	rituximab	Efficacy	yes	Genotype AA is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	A		= 0.035	OR	4.861	1.11	21.12
1450371578	rs1801274	rituximab	Efficacy	yes	Genotype AA is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	A		= 0.044	OR	10.625	1.07	105.47
1450371578	rs1801274	rituximab	Efficacy	yes	Genotype AA is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	A		= 0.066	OR	4.667	0.9	24.12
1450371578	rs1801274	rituximab	Efficacy	yes	Genotype AA is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	A		= 0.357	OR	2.487	0.35	17.31
1449716295	rs1128503	fentanyl	Efficacy	yes	Genotype AA is associated with decreased response to fentanyl in people with Neoplasms and Pain as compared to genotypes AG + GG.	G		= 0.036	OR	0.17	0.03	0.89
1450043998	rs35068180	pravastatin	Efficacy	yes	Genotypes A/del + AA are associated with increased response to pravastatin in men with Coronary Artery Disease.			= 0.04	OR	0.46	0.19	1.14
1449716341	rs1045642	fentanyl	Efficacy	no	Genotype AA is associated with decreased response to fentanyl in people with Neoplasms and Pain as compared to genotypes AG + GG.	A		= 0.14	OR	5.21	0.58	46.99
1448617859	rs4148323	irinotecan	Efficacy	no	Allele A is not associated with response to irinotecan in people with Lung Neoplasms as compared to allele G.			= 0.22	OR	1.5	0.78	2.92
1449749318	rs186364861	mercaptopurine	Dosage	yes	Allele A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.			= 0.004	HR	3.09	1.42	7.72
1448634144	rs6545816	hydroxyurea	Efficacy	no	Allele A is not associated with increased response to hydroxyurea in people with beta-Thalassemia.	A	A	= 0.07	OR	2.4	0.9	6.2
982044493	rs11269124	clonidine	Efficacy	yes	Genotypes GGGGAGCTTTCCCAGAGACCC/del + del/del are associated with increased response to clonidine in people with Liver Cirrhosis as compared to genotype GGGGAGCTTTCCCAGAGACCC/GGGGAGCTTTCCCAGAGACCC.			= 0.013	OR	3.87	2.27	33.12
1448634130	rs4671393	hydroxyurea	Efficacy	yes	Allele A is associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele G.	A	A	< 0.0001	OR	21.4	3.6	473.2
1448634124	rs766432	hydroxyurea	Efficacy	yes	Allele C is associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele A.	C	C	< 0.001	OR	9.1	2.6	42.0
1449749328	rs116855232	mercaptopurine	Dosage	yes	Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.			= 5.24E-9	HR	5.08	2.94	8.76
982044485	rs5443	clonidine	Efficacy	yes	Genotypes CT + TT are associated with increased response to clonidine in people with Liver Cirrhosis as compared to genotype CC.			< 0.001	OR	4.54	1.54	21.93
1448126131	rs1051266	methotrexate	Efficacy	yes	Genotype CT is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	C		= 0.0463	HR	3.8	1.39	10.0
1183685564	rs12708954	atomoxetine	Efficacy	yes	Allele A is associated with increased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.			< 0.01	OR	3.1	1.4	6.9
1448995913	rs7574865	etanercept	Efficacy	yes	Allele T is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to allele G.	T		= 0.02	OR	0.14	0.03	0.73
1448995921	rs7574865	adalimumab	Efficacy	no	Allele T is not associated with response to adalimumab in people with Arthritis, Rheumatoid as compared to allele G.	T		= 0.53	OR	0.58	0.11	3.16
1448995927	rs33980500	adalimumab	Efficacy	no	Allele T is not associated with response to adalimumab in people with Arthritis, Rheumatoid as compared to allele C.	T		= 0.16	OR	0.16	0.02	1.57
1450373239	rs3192723	methadone	Efficacy	no	Genotype CC is associated with decreased response to methadone in people with Heroin Dependence as compared to genotypes CT + TT.	C		= 0.4	OR	1.24	0.75	2.06
982032418	rs4358872	methadone	Dosage	no	Genotype GG is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes GT + TT.			= 0.019	OR	1.695	0.88	3.266
1448995977	rs7234029	etanercept	Efficacy	no	Allele G is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.	G		= 0.86	OR	0.88	0.22	3.5
1448125884	rs67376798	fluorouracil	Efficacy	no	Genotype AT is not associated with response to fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	A		= 0.89	HR	0.95	0.5	1.84
981848236	rs4680	venlafaxine	Efficacy	yes	Genotypes AA + AG are associated with increased response to venlafaxine in people with Anxiety Disorders as compared to genotype GG.	A		= 0.036	OR	3.26		
981848236	rs4680	venlafaxine	Efficacy	yes	Genotypes AA + AG are associated with increased response to venlafaxine in people with Anxiety Disorders as compared to genotype GG.	A		= 0.251	OR	1.71		
1448633725	rs1267067	adalimumab	Efficacy	yes	Genotype CC is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	C		= 0.008951	OR	1.719	1.145	2.581
1448633712	rs1126535	adalimumab	Efficacy	yes	Allele T is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele C.	C		= 0.006627	OR	1.871	1.19	2.942
1448633699	rs25648	adalimumab	Efficacy	yes	Allele T is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele C.	T		= 0.003902	OR	2.571	1.354	4.883
1448633692	rs2230926	adalimumab	Efficacy	yes	Allele T is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele G.	G		= 0.003733	OR	5.395	1.727	16.86
1448126187	rs1801133	methotrexate	Efficacy	no	Genotype AG is not associated with response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	A		= 0.379	HR	0.74	0.52	1.1
1446765784	rs1800497	bupropion	Efficacy	no	Genotypes AA + AG are not associated with response to bupropion in people with Tobacco Use Disorder as compared to genotype GG.	A	G	= 0.51	OR	0.82	0.46	1.48
1446765760	rs3211371	bupropion	Efficacy	no	Allele T is not associated with response to bupropion in people with Tobacco Use Disorder as compared to allele C.	C	T	= 0.44	OR	0.71	0.29	1.72
1446765769	rs3745274	bupropion	Efficacy	no	Allele T is not associated with response to bupropion in people with Tobacco Use Disorder.		T	= 0.10	OR	0.62	0.35	1.09
1446765735	rs2279343	bupropion	Efficacy	yes	Genotype AA is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes AG + GG.	A	G	= 0.03	OR	1.92	1.08	3.42
981502448	rs6966038	citalopram	Efficacy	no	Allele G is associated with increased response to citalopram in people with Depressive Disorder, Major as compared to allele A.	G	G	= 0.2	OR	1.64	1.35	1.99
1451126280	rs616147	creatine	Efficacy	yes	Genotypes AA + AG are associated with increased response to creatine in people with Amyotrophic Lateral Sclerosis as compared to genotype GG.	A		= 0.015	HR	0.48	0.22	1.07
1450372675	rs7905446	paroxetine	Efficacy	yes	Genotype TT is associated with decreased response to paroxetine in people with Bipolar Disorder as compared to genotypes GG + GT.			= 0.005	OR	5.25		
1450372715	rs7905446	escitalopram	Efficacy	yes	Genotype TT is associated with decreased response to escitalopram in people with Depression as compared to genotypes GG + GT.			= 0.008	OR	1.669		
1444668343	rs1799964	etanercept	Efficacy	no	Allele C is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele T.			= 0.72	OR	0.65	0.16	2.6
1444668343	rs1799964	etanercept	Efficacy	no	Allele C is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele T.				OR	0.53	0.17	1.64
1444668343	rs1799964	etanercept	Efficacy	no	Allele C is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele T.				OR	1.1	0.38	3.4
981502615	rs13064530	clozapine	Efficacy	no	Allele G is not associated with response to clozapine in people with Schizophrenia as compared to allele A.	A		= 0.6461	OR	2.6	1.05	6.37
1444668354	rs1800630	etanercept	Efficacy	no	Allele C is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.			= 0.7	OR	0.67	0.15	3.1
1444668354	rs1800630	etanercept	Efficacy	no	Allele C is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.				OR	0.53	0.15	1.81
1444668354	rs1800630	etanercept	Efficacy	no	Allele C is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.				OR	1.2	0.35	3.9
1450372722	rs7905446	nortriptyline	Efficacy	no	Genotype TT is not associated with response to nortriptyline in people with Depression as compared to genotypes GG + GT.			= 0.154	OR	0.694		
1444668362	rs1041981	etanercept	Efficacy	no	Allele C is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.			= 1.0	OR	0.92	0.29	2.9
1444668362	rs1041981	etanercept	Efficacy	no	Allele C is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.				OR	0.84	0.33	2.2
1444668362	rs1041981	etanercept	Efficacy	no	Allele C is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.				OR	1.1	0.47	2.5
981502629	rs4938013	clozapine	Efficacy	no	Allele C is not associated with response to clozapine in people with Schizophrenia as compared to allele A.	A		= 0.6479	OR	2.49	1.01	6.14
1448262090	rs2229193	methylphenidate	Efficacy	no	Genotype CC is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CT.	C		= 0.691	OR	1.62	0.15	17.49
1444668370	rs361525	etanercept	Efficacy	no	Allele A is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele G.			= 1.0	OR	0.7	0.04	12.0
1444668370	rs361525	etanercept	Efficacy	no	Allele A is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele G.				OR	0.66	0.07	6.2
1444668370	rs361525	etanercept	Efficacy	no	Allele A is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele G.				OR	1.0	0.11	9.3
1446896476	rs1045642	clopidogrel	Efficacy	yes	Genotype AA is associated with decreased response to clopidogrel as compared to genotypes AG + GG.			= 0.009	OR	2.39		
1444668242	rs1800629	infliximab	Efficacy	yes	Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	A		= 0.0086	OR	1.93		
748042563	rs13120400	methotrexate	Efficacy	yes	Genotype CC is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CT + TT.			= 0.03	OR	1.8		
982043600	rs776746	amlodipine	Efficacy	no	Genotype TT is not associated with response to amlodipine in people with Hypertension as compared to genotypes CC + CT.			= 0.06	HR	0.6	0.35	1.02
982043600	rs776746	amlodipine	Efficacy	no	Genotype TT is not associated with response to amlodipine in people with Hypertension as compared to genotypes CC + CT.			= 0.95	HR	0.99	0.6	1.61
982043591	rs2740574	amlodipine	Efficacy	yes	Genotypes CT + TT are associated with increased response to amlodipine in women with Hypertension as compared to genotype CC.			= 0.02	HR	3.41	1.2	9.64
982043660	rs2740574	amlodipine	Efficacy	no	Genotypes CT + TT are not associated with response to amlodipine in men with Hypertension as compared to genotype CC.			= 0.51	HR	1.31	0.58	2.93
982043660	rs2740574	amlodipine	Efficacy	no	Genotypes CT + TT are not associated with response to amlodipine in men with Hypertension as compared to genotype CC.			= 0.832	HR	1.1	0.46	2.65
1447682637	rs116855232	mercaptopurine	Other	no	Genotypes CT + TT is not associated with discontinuation of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	T		= 0.479	OR	1.48	0.57	3.85
982043687	rs2246709	amlodipine	Efficacy	no	Genotypes AG + GG are not associated with response to amlodipine in men with Hypertension as compared to genotype AA.			= 0.04	HR	2.22	1.03	4.79
982043687	rs2246709	amlodipine	Efficacy	no	Genotypes AG + GG are not associated with response to amlodipine in men with Hypertension as compared to genotype AA.			= 0.92	HR	0.82	0.46	1.85
1447682626	rs116855232	mercaptopurine	Dosage	yes	Genotypes CT + TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	T		= 0.002	OR	5.08	1.84	14.03
1450373150	rs675026	methadone	Efficacy	no	Allele G is not associated with response to methadone in people with Heroin Dependence as compared to allele A.	A		= 0.24	OR	1.81	0.66	5.04
1451159544	rs144854329	cetuximab	Efficacy	yes	Genotype del/del is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes GGTCCCACTCTTCCCACA/GGTCCCACTCTTCCCACA + GGTCCCACTCTTCCCACA/del.	GGTCCCACTCTTCCCACA	GGTCCCACTCTTCCCACA	= 0.02	OR	10.0	1.2	100.0
1448616510	rs3761548	methotrexate	Other	yes	Allele G is associated with decreased response to methotrexate in people with Psoriasis as compared to allele T.			= 0.003	OR	3.21	1.5	6.87
1448616510	rs3761548	methotrexate	Other	yes	Allele G is associated with decreased response to methotrexate in people with Psoriasis as compared to allele T.			= 0.004	OR	2.82	1.39	5.72
1450373190	rs2236258	methadone	Efficacy	no	Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele T.	C		= 0.16	OR	1.4	0.88	2.2
982043737	rs776746	amlodipine	Efficacy	no	Genotype TT is not associated with response to amlodipine in women with Hypertension as compared to genotypes CC + CT.			= 0.649	HR	1.2	0.55	2.59
982043737	rs776746	amlodipine	Efficacy	no	Genotype TT is not associated with response to amlodipine in women with Hypertension as compared to genotypes CC + CT.			= 0.72	HR	1.16	0.52	2.6
1450373183	rs2236257	methadone	Efficacy	no	Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele G.	C		= 0.8	OR	0.92	0.49	1.72
1450373174	rs2236256	methadone	Efficacy	no	Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele A.	A		= 0.33	OR	1.35	0.74	2.47
1447813645	rs78015114	lithium	Efficacy	yes	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.			= 0.033	HR	3.814		
1447813652	rs74795342	lithium	Efficacy	yes	Allele G is associated with increased response to lithium in people with Bipolar Disorder as compared to allele A.			= 0.03268	HR	3.8	1.1	13.0
1447813652	rs74795342	lithium	Efficacy	yes	Allele G is associated with increased response to lithium in people with Bipolar Disorder as compared to allele A.			= 0.033	HR	3.814		
1447813659	rs75222709	lithium	Efficacy	yes	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele G.			= 0.033	HR	3.812		
1450373168	rs6912029	methadone	Efficacy	no	Allele G is not associated with response to methadone in people with Heroin Dependence as compared to allele T.	T		= 0.58	OR	1.14	0.71	1.83
1450373223	rs2032582	methadone	Efficacy	no	Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele T.	C		= 0.71	OR	0.91	0.55	1.5
1447813633	rs79663003	lithium	Efficacy	yes	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.			= 0.033	HR	3.814		
982043698	rs2246709	amlodipine	Efficacy	no	Genotypes AG + GG are not associated with response to amlodipine in women with Hypertension as compared to genotype AA.			= 0.05	HR	2.33	1.01	5.4
982043698	rs2246709	amlodipine	Efficacy	no	Genotypes AG + GG are not associated with response to amlodipine in women with Hypertension as compared to genotype AA.			= 0.46	HR	1.39	0.59	3.27
1450373217	rs1128503	methadone	Efficacy	no	Allele A is not associated with response to methadone in people with Heroin Dependence as compared to allele G.	G		= 0.68	OR	0.9	0.54	1.48
1450373204	rs6902403	methadone	Efficacy	no	Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele T.	T		= 0.87	OR	0.95	0.54	1.68
982043719	rs776746	amlodipine	Efficacy	no	Genotype TT is not associated with response to amlodipine in men with Hypertension as compared to genotypes CC + CT.			= 0.32	HR	0.73	0.38	1.38
982043719	rs776746	amlodipine	Efficacy	no	Genotype TT is not associated with response to amlodipine in men with Hypertension as compared to genotypes CC + CT.			= 0.66	HR	0.85	0.42	1.73
1450373211	rs1045642	methadone	Efficacy	no	Allele A is not associated with response to methadone in people with Heroin Dependence as compared to allele G.	A		= 0.59	OR	0.88	0.56	1.4
1450373197	rs2236259	methadone	Efficacy	no	Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele T.	T		= 0.05	OR	0.63	0.4	1.0
982043709	rs2246709	amlodipine	Efficacy	no	Genotypes AG + GG are not associated with response to amlodipine in people with Hypertension as compared to genotype AA.			= 0.34	HR	0.77	0.46	1.31
1447944531	rs1801274	adalimumab	Efficacy	yes	Allele A is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele G.	A		= 0.017	OR	1.53	1.08	2.17
1447960897	rs1799732	nicotine	Efficacy	yes	Genotypes G/del + del/del is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype GG.			= 0.006	OR	0.44	0.25	0.79
1447960889	rs1799732	bupropion	Efficacy	yes	Genotype GG is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes G/del + del/del.			= 0.01	OR	4.99	1.42	17.62
1451258120	rs4673993	methotrexate	Efficacy	yes	Genotype CC is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	C	C	= 0.007	OR	0.3	0.12	0.75
1448423713	rs6269	quetiapine	Efficacy	yes	Allele A is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G.			= 0.008	OR	1.938	1.307	2.873
1448259816	rs1042713	salbutamol	Efficacy	no	Allele A is not associated with response to salbutamol in people with Asthma as compared to allele G.	A	A	= 0.128	OR	0.709	0.458	1.075
1448259816	rs1042713	salbutamol	Efficacy	no	Allele A is not associated with response to salbutamol in people with Asthma as compared to allele G.	A	A	= 0.215	OR	0.821	0.612	1.102
1448259816	rs1042713	salbutamol	Efficacy	no	Allele A is not associated with response to salbutamol in people with Asthma as compared to allele G.	A	A	= 0.349	OR	0.763	0.463	1.257
1448259816	rs1042713	salbutamol	Efficacy	no	Allele A is not associated with response to salbutamol in people with Asthma as compared to allele G.	A	A	= 0.843	OR	0.932	0.586	1.456
981861811	rs1800795	peginterferon alfa-2a	Efficacy	yes	Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele C.			= 0.0489	RR	0.78	0.62	1.0
1449173508	rs4680	morphine	Efficacy	yes	Allele A is associated with increased response to morphine in people with Low Back Pain as compared to allele G.	A		= 0.037	OR	0.26	0.07	0.96
1449157145	rs678849	buprenorphine	Efficacy	yes	Genotype CC is associated with decreased response to buprenorphine in people with Opioid-Related Disorders as compared to genotypes CT + TT.	C		= 0.008	RR	2.17	1.95	2.68
1449157237	rs678849	methadone	Efficacy	yes	Genotype CC is associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotypes CT + TT.	C		= 0.001	RR	0.52	0.44	0.6
981419765	rs2284018	lithium	Efficacy	yes	Genotype TT is associated with decreased response to lithium in people with Bipolar Disorder as compared to genotypes CC + CT.			= 0.036	OR	0.11		
1446735619	rs2231142	sunitinib	Efficacy	no	Genotype TT is not associated with response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.	T	G	= 0.62	OR	0.8	0.3	2.1
1451408180	rs708272	rosuvastatin	Efficacy	yes	Allele A is associated with decreased response to rosuvastatin as compared to allele G.	A		= 0.028	OR	10.56	1.27	19.86
1451408180	rs708272	rosuvastatin	Efficacy	yes	Allele A is associated with decreased response to rosuvastatin as compared to allele G.	A		= 0.030	OR	0.2	0.05	0.83
1451408180	rs708272	rosuvastatin	Efficacy	yes	Allele A is associated with decreased response to rosuvastatin as compared to allele G.	A		= 0.042	OR	8.05	0.32	15.77
1451408800	rs5882	rosuvastatin	Efficacy	yes	Allele G is associated with increased response to rosuvastatin as compared to allele A.	G		= 0.019	OR	11.61	2.07	21.5
1451408800	rs5882	rosuvastatin	Efficacy	yes	Allele G is associated with increased response to rosuvastatin as compared to allele A.	G		= 0.032	OR	13.33	1.28	25.38
981502454	rs6127921	citalopram	Efficacy	no	Allele C is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to allele A.			= 1.4	OR	0.61	0.49	0.75
1184470005	rs4244285	clopidogrel	Efficacy	yes	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	A		< 0.0001	OR	4.6	2.5	8.7
1184470013	rs12248560	clopidogrel	Efficacy	no	Genotypes CT + TT is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	T		= 0.14	OR	0.62	0.34	1.14
1451140040	rs2153628	indomethacin	Efficacy	yes	Allele G is associated with increased response to indomethacin as compared to allele A.			= 0.031	OR	1.918	1.056	3.483
1444668324	rs1799724	etanercept	Efficacy	yes	Genotypes CT + TT is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype CC.			= 0.049	OR	12.0	1.2	120.0
1451159760	rs371194629	methotrexate	Efficacy	yes	Genotype del/del is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del.	del		= 0.009	OR	2.46	1.26	4.84
1451273890	rs1059513	esomeprazole	Efficacy	yes	Genotypes CC + CT are associated with increased response to esomeprazole in children with eosinophilic esophagitis as compared to genotype TT.			= 0.028	OR	6.16	1.44	26.35
1451414440	rs1045642	pantoprazole	Efficacy	no	Genotypes AG + GG is not associated with increased response to pantoprazole in people with Helicobacter Infections as compared to genotype AA.			= 0.97	OR	0.98	0.39	2.45
1451414463	rs1143634	pantoprazole	Efficacy	no	Genotype AA is not associated with increased response to pantoprazole in people with Helicobacter Infections as compared to genotypes AG + GG.			= 0.32	OR	1.53	0.66	3.54
981962878	rs20455	pravastatin	Efficacy	yes	Genotypes AG + GG are associated with increased response to pravastatin in people with Myocardial Infarction as compared to genotype AA.			= 9.0E-4	HR	0.63	0.49	0.83
1451535103	rs11545078	methotrexate	Toxicity	yes	Genotypes AA + AG is associated with increased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.			= 0.037	OR	2.14	1.05	4.39
1451535140	rs717620	methotrexate	Toxicity	yes	Genotypes CT + TT is associated with decreased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.			= 0.026	OR	0.54	0.32	0.93
1451547391	rs1544105	methotrexate	Efficacy	yes	Genotype TT is associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	C		= 0.013	OR	0.447	0.237	0.842
1451551143	rs11615	cisplatin	Efficacy	yes	Allele A is associated with decreased response to cisplatin in women with Ovarian Neoplasms as compared to allele G.	A		= 0.003	OR	2.87	1.35	6.07
1451551246	rs3212964	cisplatin	Efficacy	no	Allele T is not associated with response to cisplatin in women with Ovarian Neoplasms as compared to allele C.	T		= 0.69	OR	1.05	0.81	1.36
1451551320	rs3212961	cisplatin	Efficacy	no	Allele A is not associated with response to cisplatin in women with Ovarian Neoplasms as compared to allele G.	A		= 0.74	OR	1.04	0.08	1.34
1451551220	rs735482	cisplatin	Efficacy	no	Allele C is not associated with response to cisplatin in women with Ovarian Neoplasms as compared to allele A.	C		= 0.24	OR	0.85	0.66	1.1
1451551177	rs3212980	cisplatin	Efficacy	no	Genotype GT is associated with increased response to cisplatin in women with Ovarian Neoplasms as compared to genotype TT.	G		= 0.012	OR	0.61	-0.59	0.89
1451551340	rs2298881	cisplatin	Efficacy	no	Allele A is not associated with response to cisplatin in women with Ovarian Neoplasms as compared to allele C.	A		= 0.79	OR	0.96	0.75	1.24
1451551149	rs3212986	cisplatin	Efficacy	yes	Allele A is associated with decreased response to cisplatin in women with Ovarian Neoplasms as compared to allele C.	A		= 0.002	OR	1.53	1.15	2.02
1451551163	rs2336219	cisplatin	Efficacy	no	Genotypes AG + GG are associated with increased response to cisplatin in women with Ovarian Neoplasms as compared to genotype AA.	A		= 0.015	OR	0.55	0.34	0.89
1451551163	rs2336219	cisplatin	Efficacy	no	Genotypes AG + GG are associated with increased response to cisplatin in women with Ovarian Neoplasms as compared to genotype AA.	A		= 0.042	OR	0.56	0.33	0.97
1451551742	rs11545078	methotrexate	Efficacy	no	Allele A is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	A		= 0.73	OR	0.57	0.12	2.73
1451551800	rs11545076	methotrexate	Efficacy	yes	Genotypes AC + CC are associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	C		= 0.04	OR	0.31	0.1	0.96
1451610560	rs3213422	leflunomide	Efficacy	yes	Genotype CC is associated with increased clinical benefit to leflunomide in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.	A		< 0.001	OR	19.13	3.699	85.23
1451610560	rs3213422	leflunomide	Efficacy	yes	Genotype CC is associated with increased clinical benefit to leflunomide in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.	A		= 0.0172	OR	4.722	1.222	14.84
1451551760	rs1800909	methotrexate	Efficacy	no	Allele G is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	G		= 0.06	OR	0.34	0.11	1.05
1451551766	rs11545077	methotrexate	Efficacy	yes	Genotypes CC + CT are associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	A		= 0.04	OR	0.31	0.1	0.96
1451551777	rs3758149	methotrexate	Efficacy	yes	Genotypes AA + AG are associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	A		= 0.04	OR	0.31	0.1	0.96
1451553044	rs6729738	cannabidiol	Efficacy	yes	Genotype CC is associated with increased response to cannabidiol in people with Epilepsy as compared to genotypes AA + AC.			= 0.001	OR	6.69	2.19	20.41
1451553125	rs12539	cannabidiol	Efficacy	yes	Genotypes CT + TT are associated with increased response to cannabidiol in people with Epilepsy as compared to genotype CC.			= 0.002	OR	3.96	1.62	9.73
1451553150	rs1339067	cannabidiol	Efficacy	yes	Genotype TT is associated with decreased response to cannabidiol in people with Epilepsy as compared to genotypes AA + AT.			= 0.001	OR	0.06	0.01	0.56
1451553420	rs3749442	cannabidiol	Efficacy	yes	Genotypes AA + AG are associated with decreased response to cannabidiol in people with Epilepsy as compared to genotype GG.			= 0.03	OR	0.36	0.15	0.85
1451635420	rs678849	disulfiram	Efficacy	yes	Genotype CC is associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotypes CT + TT.			= 0.0001	OR	0.05		
1451640200	rs12749274	naltrexone	Efficacy	yes	Allele A is associated with decreased response to naltrexone in people with Alcoholism as compared to allele G.	A		= 3.9E-8	HR	2.9		
1451640186	rs77583603	acamprosate	Efficacy	yes	Allele G is associated with decreased response to acamprosate in people with Alcoholism as compared to allele A.	G		= 3.1E-9	HR	2.38		
1451647580	rs62368105	buprenorphine	Efficacy	yes	Allele G is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele A.			= 6.76E-6	OR	1.9437		
1451647569	rs6973474	buprenorphine	Efficacy	yes	Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.			= 8.36E-6	OR	1.4043		
1451647563	rs13169373	buprenorphine	Efficacy	yes	Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.			= 9.54E-6	OR	1.4364		
1451647600	rs11782370	buprenorphine	Efficacy	yes	Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.			= 6.97E-6	OR	1.4843		
1451647605	rs756770	buprenorphine	Efficacy	yes	Allele A is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.			= 7.93E-6	OR	1.8599		
1451647610	rs7205113	buprenorphine	Efficacy	yes	Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.			= 8.05E-6	OR	1.6486		
1451679040	rs3745274	methadone	Efficacy	no	Allele T is associated with increased response to methadone in men with Opioid-Related Disorders as compared to allele G.			= 0.06	OR	0.73	0.52	1.01
1451679140	rs73568641	methadone	Efficacy	no	Allele C is associated with increased response to methadone in women with Opioid-Related Disorders as compared to allele T.			= 0.098	OR	0.71	0.47	1.07
1451679146	rs1799971	methadone	Efficacy	no	Allele G is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele A.			= 0.17	OR	0.82	0.61	1.9
1451679146	rs1799971	methadone	Efficacy	no	Allele G is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele A.			= 0.88	OR	0.97	0.7	1.36
1451679300	rs10485058	methadone	Efficacy	no	Allele G is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele A.			= 0.51	OR	1.1	0.83	1.44
1451679300	rs10485058	methadone	Efficacy	no	Allele G is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele A.			= 0.78	OR	0.96	0.71	1.3
1451683380	rs523349	abiraterone	Efficacy	yes	Genotype CC is associated with increased response to abiraterone in men with Prostatic Neoplasms as compared to genotypes CG + GG.	C		= 0.017	HR	0.43	0.2	0.87
1451683600	rs743572	abiraterone	Efficacy	no	Genotypes AG + GG are not associated with response to abiraterone in men with Prostatic Neoplasms as compared to genotype AA.	G		= 0.86	HR	0.96	0.59	1.57
1451683680	rs12529	abiraterone	Efficacy	no	Genotypes CC + CG are not associated with response to abiraterone in men with Prostatic Neoplasms as compared to genotype GG.	C		= 0.57	HR	1.18	0.66	2.12
1451683620	rs2486758	abiraterone	Efficacy	no	Genotypes CC + CT are not associated with response to abiraterone in men with Prostatic Neoplasms as compared to genotype TT.	C		= 0.20	HR	1.35	0.85	2.13
1451686940	rs115629050	sofosbuvir	Efficacy	no	Allele A is associated with decreased response to sofosbuvir in people with Hepatitis C, Chronic as compared to allele C.			= 0.0057	OR	5.43	1.64	18.01
1451686940	rs115629050	sofosbuvir	Efficacy	no	Allele A is associated with decreased response to sofosbuvir in people with Hepatitis C, Chronic as compared to allele C.	A	A	= 0.080	OR	4.09	0.85	19.73
1451686950	rs4513095	sofosbuvir	Efficacy	yes	Allele A is associated with decreased response to sofosbuvir in people with Hepatitis C, Chronic as compared to allele C.			= 0.0057	OR	5.43	1.64	18.01
1451686950	rs4513095	sofosbuvir	Efficacy	yes	Allele A is associated with decreased response to sofosbuvir in people with Hepatitis C, Chronic as compared to allele C.	A	A	= 0.035	OR	5.54	1.13	27.14
1451140100	rs1799853	indomethacin	Efficacy	no	Allele T is associated with increased response to indomethacin as compared to allele C.			= 0.174	OR	1.727	0.78	3.827
1451701983	rs324026	olanzapine	Efficacy	yes	Allele C is associated with increased clinical benefit to olanzapine in people with Schizophrenia as compared to allele T.			= 0.023	OR	2.11	1.1	4.0
1451701983	rs324026	olanzapine	Efficacy	yes	Allele C is associated with increased clinical benefit to olanzapine in people with Schizophrenia as compared to allele T.	C	C	= 0.034	OR	2.9	1.08	7.54
1451702080	rs12610827	olanzapine	Efficacy	yes	Allele T is associated with increased clinical benefit to olanzapine in people with Schizophrenia as compared to allele G.	T	T	= 0.027	OR	6.1	1.23	30.3
1451702080	rs12610827	olanzapine	Efficacy	yes	Allele T is associated with increased clinical benefit to olanzapine in people with Schizophrenia as compared to allele G.			= 0.043	OR	2.49	1.0	6.0
1451753800	rs17026688	lithium	Efficacy	yes	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.			= 6.69e-62	OR	82.2	36.2	195.6
1451753800	rs17026688	lithium	Efficacy	yes	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.			= 6.18e-43	OR	73.9	30.8	191.0
1451753800	rs17026688	lithium	Efficacy	yes	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.			= 9.17e-20	OR	180.0	32.7	1173.0
1451760997	rs3742106	tenofovir	Toxicity	yes	Genotypes AC + CC are associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotype AA.			= 0.013	OR	1.69	1.12	2.56
1451760997	rs3742106	tenofovir	Toxicity	yes	Genotypes AC + CC are associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotype AA.			= 0.018	OR	1.82	1.11	2.94
1451807080	rs7627954	risperidone	Efficacy	yes	Genotype CC is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CT + TT.	C	C	= 0.012	OR	0.18	0.04	0.87
1451761040	rs1751034	tenofovir	Toxicity	yes	Genotype TT is associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotypes CC + CT.			= 0.005	OR	1.85	1.2	2.85
1451761040	rs1751034	tenofovir	Toxicity	yes	Genotype TT is associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotypes CC + CT.			= 0.013	OR	1.85	1.14	2.94
1451806987	rs2088885	risperidone	Efficacy	yes	Genotype AA is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes AC + CC.	A	A	= 0.008	OR	0.17	0.04	0.8
1448634152	rs6706648	hydroxyurea	Efficacy	no	Allele T is not associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele C.	T	T	= 0.68	OR	0.8	0.3	2.1
1450371570	rs396991	rituximab	Efficacy	yes	Genotypes AC + CC are associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA.	C		= 0.021	OR	-1.083	-1.98	-0.18
1450371570	rs396991	rituximab	Efficacy	yes	Genotypes AC + CC are associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA.	C		= 0.077	OR	4.904	0.84	28.48
1184748726	rs17421511	methotrexate	Efficacy	no	Genotypes AG + GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.	G	G	= 0.024	OR	3.35	1.1	10.24
1184748734	rs1476413	methotrexate	Efficacy	no	Genotypes CC + CT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.	C	C	= 0.0086	OR	3.56	1.28	9.91
1184748761	rs1643650	methotrexate	Efficacy	no	Genotypes CC + CT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.	C	C	= 0.026	OR	0.31	0.1	0.96
1450812970	rs25531	nortriptyline	Efficacy	no	Allele C is not associated with response to nortriptyline in people with Tobacco Use Disorder as compared to allele T.	C		= 0.62	OR	1.11	0.75	1.64
1450812970	rs25531	nortriptyline	Efficacy	no	Allele C is not associated with response to nortriptyline in people with Tobacco Use Disorder as compared to allele T.	C		= 0.82	OR	0.96	0.65	1.4
1450812977	rs25531	bupropion	Efficacy	no	Allele C is not associated with response to bupropion in people with Tobacco Use Disorder as compared to allele T.	C		= 0.39	OR	1.19	0.79	1.79
1450812977	rs25531	bupropion	Efficacy	no	Allele C is not associated with response to bupropion in people with Tobacco Use Disorder as compared to allele T.	C		= 0.47	OR	1.16	0.78	1.72
1450812984	rs57098334	nortriptyline	Efficacy	no	Allele (AGCCCACCC)12 is not associated with response to nortriptyline in people with Tobacco Use Disorder as compared to genotypes (AGCCCACCC)10/(AGCCCACCC)10 + (AGCCCACCC)10/(AGCCCACCC)9.	(AGCCCACCC)12		= 0.15	OR	1.37	0.89	2.1
1450812984	rs57098334	nortriptyline	Efficacy	no	Allele (AGCCCACCC)12 is not associated with response to nortriptyline in people with Tobacco Use Disorder as compared to genotypes (AGCCCACCC)10/(AGCCCACCC)10 + (AGCCCACCC)10/(AGCCCACCC)9.	(AGCCCACCC)12		= 0.31	OR	1.25	0.81	1.95
1184749219	rs1042713	tiotropium	Efficacy	yes	Genotype AA is associated with increased response to tiotropium in people with Asthma as compared to genotypes AG + GG.	G		= 0.018	OR	0.21	0.07	0.59
1450812991	rs57098334	bupropion	Efficacy	no	Allele (AGCCCACCC)12 is not associated with response to bupropion in people with Tobacco Use Disorder as compared to genotypes (AGCCCACCC)10/(AGCCCACCC)10 + (AGCCCACCC)10/(AGCCCACCC)9.	(AGCCCACCC)12		= 0.57	OR	1.11	0.77	1.62
1450812991	rs57098334	bupropion	Efficacy	no	Allele (AGCCCACCC)12 is not associated with response to bupropion in people with Tobacco Use Disorder as compared to genotypes (AGCCCACCC)10/(AGCCCACCC)10 + (AGCCCACCC)10/(AGCCCACCC)9.	(AGCCCACCC)12		= 0.87	OR	1.03	0.71	1.48
1447963626	rs1695	dimethyl fumarate	Efficacy	yes	Genotype GG is associated with decreased response to dimethyl fumarate in people with Psoriasis as compared to genotypes AA + AG.			= 0.0017	OR	43.4	4.2	511.1
1448994492	rs1045642	clopidogrel	Efficacy	yes	Genotype GG is associated with increased resistance to clopidogrel in people with Hypertension as compared to genotype AA.	G	G	= 0.024	OR	0.073		
1447521111	rs179008	imiquimod	Efficacy	yes	Allele A is associated with increased response to imiquimod in people with Carcinoma, Basal Cell as compared to allele T.			= 0.02	OR	7.25	1.43	36.69
1447521111	rs179008	imiquimod	Efficacy	yes	Allele A is associated with increased response to imiquimod in people with Carcinoma, Basal Cell as compared to allele T.			< 0.05	OR	29.29	1.0	860.0
1448635155	rs17655	platinum	Efficacy	yes	Genotype GG is associated with increased response to platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.			= 0.027	OR	1.57	1.05	2.34
1451206568	rs1799752	salvianolic acid b	Efficacy	yes	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to salvianolic acid b in people with Coronary Disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	(289BP ALU)		= 0.015	OR	2.414	1.189	4.903
1450928092	rs6706232	risperidone	Efficacy	no	Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.	A	A	> 0.05	OR	0.41	0.2	0.85
1450928098	rs1056827	risperidone	Efficacy	no	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.	A	A	> 0.05	OR	4.37	1.2	15.91
1448602262	rs2108622	warfarin	Dosage	no	Genotypes CT + TT is not associated with increased dose of warfarin in people with Atrial Fibrillation, Cardiomyopathies, heart valve replacement, Peripheral Vascular Diseases, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.	C		= 0.128	OR	5.47	0.61	48.79
1450928104	rs10012	risperidone	Efficacy	no	Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.	C	C	> 0.05	OR	3.16	1.0	9.93
1449748447	rs1128503	tacrolimus	Efficacy	yes	Genotype AA is associated with increased response to tacrolimus in people with Nephrotic Syndrome as compared to genotypes AG + GG.	A		= 0.018	OR	12.085	1.535	95.148
1449748454	rs2032582	tacrolimus	Efficacy	yes	Genotypes AA + TT is associated with increased response to tacrolimus in people with Nephrotic Syndrome as compared to genotypes CC + CT.			= 0.042	OR	8.683	1.08	69.819
1450928144	rs4818	risperidone	Efficacy	no	Allele G is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	C	C	> 0.05	OR	0.42	0.18	0.96
1450928156	rs4680	risperidone	Efficacy	no	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.	A	A	> 0.05	OR	3.06	1.13	8.28
1450928162	rs1128503	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.	G	G	= 1	OR	0.953	0.737	1.231
1450928162	rs1128503	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.	G	G	= 1	OR	1.025	0.766	1.373
1450928162	rs1128503	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.	G	G	= 1	OR	0.557	0.281	1.105
1450928113	rs6280	risperidone	Efficacy	no	Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele T.	C	C	> 0.05	OR	2.6	1.09	6.2
1450928121	rs362267	risperidone	Efficacy	no	Allele T is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.	T	T	> 0.05	OR	2.5	1.1	5.7
1444702812	rs1045642	phenobarbital	Efficacy	yes	Genotype GG is associated with increased resistance to phenobarbital in people with Epilepsy as compared to genotype AA.			= 0.039	OR	3.962	1.075	14.61
1450928129	rs362306	risperidone	Efficacy	no	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.	A	A	> 0.05	OR	2.22	1.01	4.9
1450928135	rs2515641	risperidone	Efficacy	no	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	A	A	> 0.05	OR	2.22	1.01	4.9
1450928209	rs1801133	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.	G	G	= 1	OR	0.953	0.742	1.224
1450928209	rs1801133	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.	G	G	= 1	OR	1.184	0.886	1.582
1450928209	rs1801133	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.	G	G	= 1	OR	1.13	0.6	2.128
1450928233	rs3803300	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	C	C	= 1	OR	1.078	0.831	1.399
1450928233	rs3803300	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	C	C	= 1	OR	1.207	0.895	1.628
1450928233	rs3803300	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	C	C	= 1	OR	0.628	0.319	1.237
1450928193	rs1799978	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	C	C	= 1	OR	1.067	0.785	1.452
1450928193	rs1799978	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	C	C	= 1	OR	1.182	0.83	1.683
1450928193	rs1799978	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	C	C	= 1	OR	0.547	0.23	1.302
1450928272	rs4483927	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	G	G	= 0.274	OR	0.882	0.685	1.136
1450928272	rs4483927	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	G	G	= 0.274	OR	0.357	0.171	0.744
1450928272	rs4483927	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	G	G	= 1	OR	0.968	0.728	1.288
1450928280	rs6265	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	C	C	= 1	OR	1.054	0.824	1.349
1450928280	rs6265	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	C	C	= 1	OR	0.959	0.725	1.27
1450928280	rs6265	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	C	C	= 1	OR	1.183	0.632	2.213
1450928288	rs6295	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	G	G	= 0.274	OR	1.118	0.841	1.486
1450928288	rs6295	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	G	G	= 0.274	OR	2.417	1.231	4.745
1450928288	rs6295	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	G	G	= 1	OR	1.005	0.727	1.39
1450928296	rs6311	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	C	C	= 1	OR	1.065	0.832	1.365
1450928296	rs6311	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	C	C	= 1	OR	1.064	0.803	1.41
1450928296	rs6311	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	T	T	= 1	OR	1.411	0.757	2.629
1450928241	rs3787429	risperidone	Efficacy	no	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	T	T	= 1	OR	1.001	0.763	1.311
1450928241	rs3787429	risperidone	Efficacy	no	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	T	T	= 1	OR	1.015	0.748	1.376
1450928241	rs3787429	risperidone	Efficacy	no	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	T	T	= 1	OR	0.756	0.377	1.514
1450928254	rs3813928	risperidone	Efficacy	no	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	A	A	= 1	OR	1.188	0.825	1.709
1450928254	rs3813928	risperidone	Efficacy	no	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	A	A	= 1	OR	1.296	0.847	1.982
1450928254	rs3813928	risperidone	Efficacy	no	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	A	A	= 1	OR	1.006	0.419	2.418
1450928264	rs3818929	risperidone	Efficacy	no	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	A	A	= 1	OR	0.967	0.69	1.356
1450928264	rs3818929	risperidone	Efficacy	no	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	A	A	= 1	OR	1.326	0.873	2.013
1450928264	rs3818929	risperidone	Efficacy	no	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	A	A	= 1	OR	0.642	0.294	1.399
1450928304	rs6313	risperidone	Efficacy	no	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	A	A	= 1	OR	1.092	0.851	1.401
1450928304	rs6313	risperidone	Efficacy	no	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	A	A	= 1	OR	1.123	0.845	1.492
1450928304	rs6313	risperidone	Efficacy	no	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	A	A	= 1	OR	1.274	0.681	2.384
981419300	rs165599	bupropion	Efficacy	yes	Genotypes AA + AG are associated with increased response to bupropion in smokers as compared to genotype GG.	A		= 0.04	OR	2.21	1.36	3.0
1448601916	rs9934438	warfarin	Dosage	yes	Genotype AG is associated with increased dose of warfarin in people with Atrial Fibrillation, Cardiomyopathies, heart valve replacement, Peripheral Vascular Diseases, Pulmonary Embolism and Venous Thrombosis as compared to genotype GG.	A		= 0.019	OR	0.06	0.01	0.63
1448601904	rs4570625	venlafaxine	Efficacy	no	Allele G is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele T.			= 0.009	OR	1.31	0.88	1.94
1447983363	rs2071303	adalimumab	Efficacy	yes	Genotypes CC + CT are associated with increased response to adalimumab in people with Crohn Disease as compared to genotype TT.			= 0.009	OR	4.832	1.519	15.367
827921493	rs121434568	erlotinib	Efficacy	yes	Genotypes GT + TT are associated with decreased response to erlotinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.			= 0.02	HR	1.68		
982015348	rs2270007	citalopram	Efficacy	yes	Genotypes CC + CG are associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype GG.	C	C	= 0.006	OR	2.93	1.24	6.9
1184467438	rs1801133	methotrexate	Efficacy	no	Genotype AG is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.			= 0.2	OR	0.82	0.6	1.11
1184467438	rs1801133	methotrexate	Efficacy	no	Genotype AG is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.			= 0.29	OR	0.76	0.45	1.26
1184467445	rs1801131	methotrexate	Efficacy	no	Genotype GT is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.			= 0.26	OR	1.34	0.81	2.22
1296666538	rs10213440	metformin	Efficacy	no	Allele T is not associated with response to metformin in people with Diabetes Mellitus as compared to allele C.	C	T	= 0.435	OR	1.4	0.6	3.24
1184467466	rs1801131	methotrexate	Efficacy	no	Genotype TT is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.			= 0.72	OR	0.87	0.39	1.91
1184467466	rs1801131	methotrexate	Efficacy	no	Genotype TT is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.			= 0.75	OR	1.09	0.64	1.86
1449753059	rs678849	buprenorphine	Efficacy	yes	Genotype CC is associated with decreased response to buprenorphine in people with Opioid-Related Disorders as compared to genotypes CT + TT.			= 0.021	RR	1.69	1.59	1.79
1184467478	rs1801133	methotrexate	Efficacy	no	Genotype AA is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.			= 0.27	OR	0.76	0.46	1.24
1184467478	rs1801133	methotrexate	Efficacy	no	Genotype AA is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.			= 0.32	OR	0.67	0.3	1.49
1445296275	rs1799983	salvianolic acid b	Efficacy	yes	Genotype GG is associated with increased response to salvianolic acid b in people with Coronary Disease as compared to genotypes GT + TT.	T		= 0.028	OR	2.45	1.099	5.44
1296666461	rs4810083	metformin	Efficacy	no	Allele T is not associated with response to metformin in people with Diabetes Mellitus as compared to allele C.	C	T	= 0.680	OR	0.89	0.51	1.55
1296666425	rs249429	metformin	Efficacy	no	Allele T is not associated with response to metformin in people with Diabetes Mellitus as compared to allele C.	C	T	= 0.230	OR	0.68	0.36	0.128
827807008	rs2106089	benazepril	Efficacy	yes	Allele G is associated with response to benazepril in men with Hypertension as compared to allele A.			= 0.001	OR	1.9	1.3	2.8
1449179722	rs683369	imatinib	Efficacy	yes	Genotypes CG + GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC.			= 0.032	OR	0.64	0.42	0.96
827806987	rs4762	benazepril	Efficacy	yes	Genotype GG is associated with response to benazepril in men with Hypertension as compared to genotype AA.			= 0.001	OR	1.9	1.3	2.8
1449179728	rs776746	imatinib	Efficacy	yes	Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T.			< 0.001	OR	2.08	1.47	2.95
982032025	rs10835210	methadone	Dosage	no	Genotype CC is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AA + AC.			= 0.019	OR	2.142	0.986	4.655
1183615597	rs2229437	benazepril	Efficacy	yes	Genotypes GG + GT are associated with decreased response to benazepril in people with Hypertension as compared to genotype TT.	T		= 0.005	OR	0.6	0.4	0.9
1449163647	rs258751	prednisone	Efficacy	yes	Allele A is associated with decreased resistance to prednisone in people with Nephrotic Syndrome as compared to allele G.	A	A	= 0.022	OR	0.31	0.11	0.84
1451359144	rs1042098	heroin	Efficacy	no	Allele G is not associated with response to heroin as compared to allele A.	G		= 0.587	OR	1.12	0.744	1.687
1449163663	rs10052957	prednisone	Efficacy	yes	Allele A is associated with decreased resistance to prednisone in people with Nephrotic Syndrome as compared to allele G.	A	A	= 0.038	OR	0.39	0.16	0.95
1449163673	rs6196	prednisone	Efficacy	yes	Allele G is associated with decreased resistance to prednisone in people with Nephrotic Syndrome as compared to allele A.	A	A	= 0.008	OR	0.26	0.1	0.7
982032363	rs2289658	methadone	Dosage	no	Genotypes CC + CT are associated with increased dose of methadone in people with Heroin Dependence as compared to genotype TT.			= 0.019	OR	1.592	0.586	4.329
1450933220	rs2231137	imatinib	Dosage	yes	Genotypes CT + TT are associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	T		= 0.0002	OR	7.35	2.55	21.2
982032312	rs2120266	methadone	Dosage	no	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.			= 0.019	OR	1.917	0.198	18.611
1448097395	rs717620	tamoxifen	Efficacy	yes	Genotype CT is associated with increased response to tamoxifen in women Breast Neoplasms as compared to genotype CC.	C	C	= 0.040	HR	2.34	1.94	5.27
1450376218	rs12083537	tocilizumab	Efficacy	yes	Genotype AA is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	G		= 0.018	OR	0.37	0.14	0.92
1450376218	rs12083537	tocilizumab	Efficacy	yes	Genotype AA is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	G		= 0.044	OR	0.23	0.04	1.03
1450933245	rs2231142	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.	T		= 0.949	OR	1.03	0.43	2.49
1451359324	rs27072	heroin	Dosage	no	Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele C.	T		= 0.161	OR	1.177	0.937	1.477
1451359330	rs1042098	heroin	Dosage	no	Allele G is not associated with dose of heroin in people with Heroin Dependence as compared to allele A.	G		= 0.714	OR	0.937	0.662	1.326
1296666368	rs3792269	metformin	Efficacy	yes	Allele G is associated with decreased response to metformin in people with Diabetes Mellitus as compared to allele A.	G	A	= 0.02	OR	0.27	0.12	0.62
1450933302	rs2631372	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	G		= 0.497	OR	1.6	0.41	6.26
1450933302	rs2631372	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	G		= 0.552	OR	1.28	0.56	2.91
1451359283	rs12666409	heroin	Dosage	no	Allele A is not associated with dose of heroin in people with Heroin Dependence as compared to allele T.	A		= 0.333	OR	0.907	0.745	1.105
1450933310	rs628031	imatinib	Dosage	no	Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	A		= 0.660	OR	1.28	0.43	3.84
1450933310	rs628031	imatinib	Dosage	no	Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	A		= 0.666	OR	1.21	0.51	2.91
1451359381	rs6347	heroin	Dosage	no	Allele C is not associated with dose of heroin in people with Heroin Dependence as compared to allele T.	C		= 0.371	OR	0.871	0.644	1.179
1450933392	rs1045642	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.	A		= 0.188	OR	0.48	0.16	1.43
1450933392	rs1045642	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.	A		= 0.410	OR	0.69	0.29	1.66
1447982567	rs10011796	allopurinol	Efficacy	no	Genotypes CT + TT are not associated with response to allopurinol in people with Gout as compared to genotype CC.	C	T	= 0.446	OR	0.85	0.54	1.31
1450933400	rs868755	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	T		= 0.096	OR	0.32	0.08	1.23
1450933400	rs868755	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	T		= 0.571	OR	0.79	0.34	1.8
1450933408	rs1050152	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.111	OR	0.5	0.21	1.18
1450933408	rs1050152	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.244	OR	0.51	0.17	1.58
1447982552	rs2231142	allopurinol	Efficacy	yes	Genotypes GT + TT are associated with decreased response to allopurinol in people with Gout as compared to genotype GG.	G	T	= 0.00063	OR	2.78	1.57	5.09
1450933416	rs2740574	imatinib	Dosage	no	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.	C		= 0.172	OR	2.14	0.72	6.35
1444935134	rs622342	metformin	Efficacy	yes	Genotypes AC + CC is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	A		= 0.0009	OR	4.1	1.78	9.43
982032521	rs7118900	methadone	Dosage	no	Genotypes AA + AG are associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.			= 0.019	OR	1.755	0.951	3.236
1451359361	rs10770140	heroin	Dosage	no	Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele C.	C		= 0.721	OR	0.933	0.637	1.366
1450933384	rs6935207	imatinib	Dosage	no	Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	A		= 0.653	OR	0.69	0.14	3.41
1450933384	rs6935207	imatinib	Dosage	no	Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	A		= 0.881	OR	0.94	0.41	2.16
1450933468	rs1800812	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	T		= 0.446	OR	0.71	0.29	1.71
1450933468	rs1800812	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	T		= 0.512	OR	0.5	0.06	4.01
1451359466	rs5320	heroin	Dosage	no	Allele A is not associated with dose of heroin in people with Heroin Dependence as compared to allele G.	A		= 0.200	OR	0.83	0.624	1.104
1450933478	rs1800813	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.	G		= 0.124	OR	0.47	0.18	1.23
1450933478	rs1800813	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.	G		= 0.669	OR	0.63	0.08	5.17
1450933424	rs1057868	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.486	OR	1.5	0.48	4.65
1450933424	rs1057868	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.635	OR	1.23	0.52	2.91
1450933432	rs717620	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.523	OR	0.5	0.06	4.22
1450933432	rs717620	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.744	OR	1.15	0.5	2.65
1450933440	rs1048943	imatinib	Dosage	no	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.	C		= 0.274	OR	0.31	0.04	2.52
1451359420	rs10770141	heroin	Dosage	no	Allele G is not associated with dose of heroin in people with Heroin Dependence as compared to allele A.	A		= 0.597	OR	0.899	0.605	1.336
1447949684	rs2032582	atorvastatin	Efficacy	yes	Genotypes AA + AC are associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype CC.	A		< 0.05	OR	2.97	1.08	8.17
1450933448	rs4149117	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	T		= 0.969	OR	0.98	0.37	2.61
1451359426	rs3842727	heroin	Dosage	no	Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele G.	G		= 0.884	OR	0.962	0.576	1.608
655387811	rs2853539	methotrexate	Efficacy	yes	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.			= 0.001	OR	2.76	1.5	5.07
1450933522	rs2305948	imatinib	Dosage	no	Genotype CT is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	T		= 0.503	OR	0.65	0.18	2.29
1451359501	rs27072	methadone	Dosage	no	Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele C.	T		= 0.251	OR	0.858	0.66	1.115
1450933529	rs1570360	imatinib	Dosage	no	Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	A		= 0.292	OR	1.58	0.68	3.69
1450933529	rs1570360	imatinib	Dosage	no	Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	A		= 0.360	OR	1.79	0.51	6.23
1450933537	rs2010963	imatinib	Dosage	no	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	C		= 0.065	OR	0.14	0.02	1.13
1450933537	rs2010963	imatinib	Dosage	no	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	C		= 0.158	OR	0.54	0.23	1.27
1451359521	rs129882	methadone	Dosage	no	Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele C.	T		= 0.613	OR	1.062	0.842	1.338
1450933545	rs25648	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.313	OR	1.05	0.43	2.54
1450933489	rs2228230	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.992	OR	1.0	0.43	2.34
1450376478	rs5569	methylphenidate	Efficacy	no	Genotypes AA + AG are associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG.			= 0.609	OR	0.838	0.425	1.651
1450933497	rs35597368	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.957	OR	0.98	0.39	2.42
1450376471	rs28386840	methylphenidate	Efficacy	no	Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.			= 0.093	OR	2.329	0.868	6.253
1450933505	rs1870377	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.	T		= 0.621	OR	0.58	0.07	4.98
1450933505	rs1870377	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.	T		= 0.634	OR	1.23	0.53	2.83
1450933513	rs2071559	imatinib	Dosage	no	Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	A		= 0.669	OR	0.83	0.35	1.96
1450933513	rs2071559	imatinib	Dosage	no	Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	A		= 0.975	OR	0.98	0.31	3.12
1451359577	rs6356	methadone	Dosage	no	Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele C.	T		= 0.258	OR	1.19	0.88	1.608
1450933585	rs1799939	imatinib	Dosage	no	Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	A		= 0.294	OR	0.58	0.21	1.61
1450933585	rs1799939	imatinib	Dosage	no	Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	A		= 0.593	OR	1.58	0.3	8.36
1451359566	rs10770141	methadone	Dosage	no	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.	A		= 0.142	OR	1.369	0.899	2.085
1451359571	rs3842727	methadone	Dosage	no	Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele G.	G		= 0.458	OR	1.239	0.703	2.181
1450933593	rs1933437	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.	G		= 0.367	OR	0.53	0.13	2.1
1450933593	rs1933437	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.	G		= 0.406	OR	1.43	0.61	3.34
1451359593	rs5320	methadone	Dosage	no	Allele A is not associated with dose of methadone in people with Heroin Dependence as compared to allele G.	A		= 0.509	OR	0.895	0.644	1.244
1450933601	rs7993418	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.	G		= 0.524	OR	1.3	0.58	2.93
1451359581	rs12666409	methadone	Dosage	no	Allele A is not associated with dose of methadone in people with Heroin Dependence as compared to allele T.	A		= 0.331	OR	0.896	0.718	1.118
1451359587	rs11575553	methadone	Dosage	no	Allele A is not associated with dose of methadone in people with Heroin Dependence as compared to allele G.	A		= 0.673	OR	1.078	0.761	1.526
1451359540	rs10770140	methadone	Dosage	no	Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele C.	C		= 0.213	OR	1.305	0.87	1.957
1450933553	rs3025039	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.737	OR	0.69	0.08	5.98
1450933553	rs3025039	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.824	OR	0.9	0.34	2.35
1451359561	rs6347	methadone	Dosage	no	Allele C is not associated with dose of methadone in people with Heroin Dependence as compared to allele T.	C		= 0.618	OR	1.09	0.777	1.528
1450933569	rs833061	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.551	OR	1.4	0.46	4.22
1450933569	rs833061	imatinib	Dosage	no	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	T		= 0.641	OR	1.27	0.47	3.42
982047043	rs1800471	rituximab	Efficacy	yes	Genotype CG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype GG.			= 0.008	OR	2.6	1.4	4.6
982047043	rs1800471	rituximab	Efficacy	yes	Genotype CG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype GG.			= 0.025	OR	1.6	1.3	1.9
982047038	rs1800470	rituximab	Efficacy	yes	Genotype AG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA.			= 0.002	OR	1.6	1.2	2.3
982047038	rs1800470	rituximab	Efficacy	yes	Genotype AG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA.			= 0.008	OR	2.6	1.4	4.6
1451359640	rs129915	methadone	Dosage	no	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.	G		= 0.187	OR	0.861	0.689	1.075
1451359651	rs1042098	methadone	Dosage	no	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.	G		= 0.102	OR	0.72	0.485	1.069
1449164214	rs6265	methadone	Efficacy	no	Allele T is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele C.	T		= 0.260	OR	1.37	0.792	2.371
1296599948	rs1801131	methotrexate	Toxicity	no	Genotype GG is not associated with response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.			= 0.12	RR	0.75	0.52	1.08
1296599948	rs1801131	methotrexate	Toxicity	no	Genotype GG is not associated with response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.			= 0.12	RR	0.25	0.04	1.43
1296599948	rs1801131	methotrexate	Toxicity	no	Genotype GG is not associated with response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.			= 0.69	RR	0.93	0.63	1.35
1449164221	rs1799978	methadone	Efficacy	no	Allele C is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele T.	C		= 0.603	OR	1.28	0.511	3.182
982047201	rs4680	nicotine	Efficacy	yes	Genotype GG is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG.			= 0.02	OR	2.21	1.15	4.24
1450376730	rs1800544	methylphenidate	Efficacy	not stated	Genotype GG is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity.			= 0.045	OR	5.655		
1450180162	rs717620	simvastatin	Efficacy	yes	Genotypes CT + TT is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotype CC.	T	T	= 0.002	OR	2.311	1.373	3.89
1450180162	rs717620	simvastatin	Efficacy	yes	Genotypes CT + TT is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotype CC.			= 0.034	OR	1.856	1.048	3.285
1449164371	rs13058338	idarubicin	Efficacy	yes	Genotype AT is associated with increased response to idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype TT.	A		= 0.016	OR	2.8	1.21	6.5
1449164364	rs1883112	idarubicin	Efficacy	yes	Genotype AA is associated with increased response to idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.	A		= 0.035	OR	3.7	1.1	12.8
1450180222	rs5569	methylphenidate	Efficacy	yes	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.			= 0.0007	OR	1.73	1.26	2.37
1450180215	rs28386840	methylphenidate	Efficacy	yes	Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.			< 0.0001	OR	2.93	1.76	4.9
1451359880	rs4680	propranolol	Efficacy	no	Genotype GG is associated with increased response to propranolol in people with Temporomandibular joint-pain-dysfunction syndrome as compared to genotype AA.	G			OR	10.9	2.4	50.7
1450180291	rs1800544	methylphenidate	Efficacy	yes	Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.			= 0.01	OR	1.69	1.12	2.55
1450180321	rs6551665	methylphenidate	Efficacy	no	Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G.			= 0.59	OR	1.07	0.84	1.37
1450180328	rs1947274	methylphenidate	Efficacy	no	Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.			= 0.70	OR	0.95	0.71	1.26
1450180302	rs4680	methylphenidate	Efficacy	yes	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.			= 0.02	OR	1.4	1.04	1.87
1450376953	rs3792452	methylphenidate	Efficacy	not stated	Genotype CT is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.			= 0.011	OR	4.38	1.4	13.75
1450376953	rs3792452	methylphenidate	Efficacy	not stated	Genotype CT is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.			= 0.044	OR	2.43	1.03	5.77
1450376953	rs3792452	methylphenidate	Efficacy	not stated	Genotype CT is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.			= 0.438	OR	1.4	0.6	3.31
827921971	rs16969968	Drugs used in nicotine dependence	Other	yes	Allele A is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.			= 9.7E-7	HR	0.48	0.36	0.64
827921983	rs680244	Drugs used in nicotine dependence	Other	yes	Allele C is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.			= 9.7E-7	HR	0.48	0.36	0.64
1447949071	rs3077	peginterferon alfa-2b	Efficacy	yes	Genotype GG is associated with increased response to peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to genotypes AA + AG.			= 0.011	OR	2.78	1.27	6.11
1447949081	rs12979860	peginterferon alfa-2b	Efficacy	no	Genotype CC is not associated with increased response to peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to genotype CT.			= 0.691	OR	1.24	0.43	3.6
827921996	rs16969968	Drugs used in nicotine dependence	Other	yes	Allele G is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.			= 2.7E-8	HR	0.48	0.37	0.62
827922003	rs680244	Drugs used in nicotine dependence	Other	yes	Allele T is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.			= 2.7E-8	HR	0.48	0.37	0.62
1449557869	rs1801394	methotrexate	Efficacy	yes	Allele A is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.			= 0.004	OR	1.39	1.1	1.8
1449557891	rs35592	methotrexate	Efficacy	no	Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.			= 0.2	OR	1.19	0.9	1.5
1449557915	rs12995526	methotrexate	Efficacy	no	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.			= 0.1	OR	0.85	0.7	1.1
1449557909	rs4673990	methotrexate	Efficacy	no	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.			= 0.009	OR	0.73	0.6	0.9
827823546	rs1012335	glatiramer acetate	Efficacy	yes	Allele G is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele C.	G	G	= 0.0056	OR	0.072	0.02	0.28
1449557927	rs2372536	methotrexate	Efficacy	no	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.			= 0.009	OR	0.72	0.6	0.9
827823538	rs333	glatiramer acetate	Efficacy	yes	Allele del is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele GTCAGTATCAATTCTGGAAGAATTTCCAGACA.	del	del	= 0.013	OR	0.065	0.008	0.52
1449557921	rs16853834	methotrexate	Efficacy	no	Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.			= 0.6	OR	0.91	0.7	1.3
1449557945	rs1127354	methotrexate	Efficacy	no	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.			= 0.2	OR	0.74	0.5	1.1
1449557951	rs2236225	methotrexate	Efficacy	no	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.			= 0.8	OR	1.03	0.8	1.3
827823495	rs1800469	glatiramer acetate	Efficacy	yes	Allele A is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.	A	A	= 0.049	OR	0.43	0.23	0.81
1449557987	rs2650972	methotrexate	Efficacy	no	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.			= 0.035	OR	1.28	1.02	1.6
1449164775	rs1051266	methotrexate	Toxicity	yes	Genotypes CT + TT is associated with decreased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	T		= 0.02	HR	0.55	0.33	0.93
1449557981	rs7624766	methotrexate	Efficacy	no	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.			= 0.3	OR	1.13	0.9	1.4
1449558004	rs1901633	methotrexate	Efficacy	no	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.			= 0.3	OR	0.88	0.7	1.1
1449164791	rs1128503	methotrexate	Toxicity	no	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	A		= 0.74	HR	1.1	0.62	1.95
1449557998	rs5836788	methotrexate	Efficacy	no	Allele del is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.			= 1.0	OR	1.0	0.8	1.3
1449164801	rs1045642	methotrexate	Toxicity	no	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	G		= 0.74	HR	1.1	0.59	2.07
1449558022	rs6064463	methotrexate	Efficacy	no	Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.			= 0.2	OR	1.17	0.9	1.5
1449164807	rs4149056	methotrexate	Toxicity	no	Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	C		= 0.93	HR	0.98	0.57	1.66
1449164819	rs2306283	methotrexate	Toxicity	no	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	G		= 0.5	HR	0.84	0.49	1.42
1449164813	rs11045879	methotrexate	Toxicity	no	Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	C		= 0.69	HR	0.9	0.53	1.53
1449558039	rs6506569	methotrexate	Efficacy	no	Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.			= 0.3	OR	0.89	0.7	1.1
1449558033	rs162040	methotrexate	Efficacy	no	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.			= 0.1	OR	1.35	0.98	1.9
1449164825	rs2231137	methotrexate	Toxicity	no	Genotype CC is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CT.	T		= 0.11	HR	0.2	0.03	1.53
1449558056	rs2847153	methotrexate	Efficacy	no	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.			= 0.9	OR	1.02	0.8	1.4
1449164833	rs2231142	methotrexate	Toxicity	no	Allele G is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	T		= 0.38	HR	1.32	0.69	2.53
827807029	rs7079	benazepril	Efficacy	yes	Genotype GG is associated with response to benazepril in women with Hypertension as compared to genotype TT.			= 0.001	OR	3.5	2.0	5.9
1449558050	rs2244500	methotrexate	Efficacy	no	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.			= 0.4	OR	0.89	0.7	1.1
1449164839	rs2804402	methotrexate	Toxicity	no	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	G		= 0.15	HR	1.79	0.8	4.01
827807021	rs2640543	benazepril	Efficacy	yes	Genotype GG is associated with response to benazepril in women with Hypertension as compared to genotype AA.			< 0.001	OR	3.5	2.0	5.9
1449164851	rs2273697	methotrexate	Toxicity	no	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	A		= 0.48	HR	1.2	0.71	2.05
1449164845	rs717620	methotrexate	Toxicity	no	Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	T		= 0.57	HR	0.86	0.5	1.46
1184747648	rs2231142	sulfasalazine	Efficacy	yes	Genotypes GT + TT are associated with increased response to sulfasalazine in people with Arthritis, Rheumatoid as compared to genotype GG.	T		= 0.025	OR	3.34	1.17	9.64
1449164880	rs3394	methotrexate	Toxicity	no	Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	T		= 0.84	HR	1.05	0.63	1.77
1449164906	rs2298191	methotrexate	Toxicity	no	Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	T		= 0.9	HR	1.03	0.62	1.74
769172931	rs6277	methadone	Efficacy	no	Genotype GG is associated with decreased response to methadone in people with Substance-Related Disorders.	A		= 0.075	OR	2.4	1.2	4.8
655385715	rs5443	sumatriptan	Efficacy	yes	Genotype CT is associated with increased response to sumatriptan in people with Cluster Headache as compared to genotype CC.	C		= 0.0074	OR	2.96	1.34	6.56
1451144600	rs3918242	ulinastatin	Efficacy	yes	Allele T is associated with increased response to ulinastatin in people with Pancreatitis as compared to allele C.	T	T	< 0.001	OR	0.372	0.221	0.627
1451144564	rs243865	ulinastatin	Efficacy	yes	Allele T is associated with decreased response to ulinastatin in people with Pancreatitis as compared to allele C.	T	T	< 0.001	OR	4.121	2.523	6.731
1451357620	rs6990851	anastrozole	Efficacy	yes	Allele G is associated with increased response to anastrozole in women with Breast Neoplasms as compared to allele A.			= 4.83E-6	HR	0.56		
981750318	rs2314339	lithium	Efficacy	yes	Allele T is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele C.			< 0.05	OR	3.56	1.18	10.76
1444936658	rs1045642	sunitinib	Efficacy	yes	Genotype GG is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.	G		= 0.05	RR	4.57	1.08	19.42
1449752258	rs1801274	cetuximab	Efficacy	yes	Genotype AA is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes AG + GG.	G		< 0.001	HR	0.61	0.5	0.74
1449752258	rs1801274	cetuximab	Efficacy	yes	Genotype AA is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes AG + GG.	G		< 0.001	OR	0.71	0.63	0.8
1449752258	rs1801274	cetuximab	Efficacy	yes	Genotype AA is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes AG + GG.	G		= 0.02	HR	0.8	0.66	0.97
1450931941	rs45476395	sertraline	Efficacy	no	Allele T is not associated with response to sertraline in people with Depressive Disorder, Major as compared to allele A.	T		= 0.920	OR	0.9	0.34	2.57
1184483081	rs1045642	cyclosporine	Efficacy	yes	Allele A is associated with decreased response to cyclosporine in people with Psoriasis as compared to allele G.	A		= 0.0075	OR	2.995	1.448	6.226
1450374888	rs2070762	methylphenidate	Efficacy	yes	Genotype GG is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.			= 0.0055	OR	4.34	1.54	12.2
1450374888	rs2070762	methylphenidate	Efficacy	yes	Genotype GG is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.			= 0.017	OR	4.33	1.21	15.5
1449752269	rs396991	cetuximab	Efficacy	no	Allele C is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele A.	A		= 0.39	HR	0.93	0.78	1.1
1449752269	rs396991	cetuximab	Efficacy	no	Allele C is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele A.	A		= 0.44	HR	0.93	0.78	1.11
1449752269	rs396991	cetuximab	Efficacy	no	Allele C is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele A.	A		= 0.80	HR	0.99	0.87	1.12
1450931954	rs5441	sertraline	Efficacy	yes	Genotype GG is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to genotypes AA + AG.	G		= 0.004	OR	5.9	1.66	21.99
1444936434	rs10210302	adalimumab	Efficacy	yes	Genotypes CT + TT is associated with increased response to adalimumab in people with Crohn Disease as compared to genotype CC.	C		= 8.11E-4	OR	9.44	2.49	35.83
1451161440	rs11280056	methotrexate	Toxicity	no	Allele del is associated with increased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele TTAAAGTTA.			= 0.07	OR	2.56	0.89	7.34
608431344	rs2284017	lithium	Efficacy	not stated	Allele C is associated with increased response to lithium in people with Bipolar Disorder as compared to allele T.			= 0.029	OR	0.35		
1449179077	rs628031	imatinib	Efficacy	yes	Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.			= 0.011	OR	0.58	0.38	0.88
655386443	rs11042725	paroxetine	Efficacy	yes	Genotype CC is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotypes AA + AC.			= 0.001	OR	0.075	0.019	0.295
1448589873	rs45445694	methotrexate	Efficacy	yes	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.			= 0.01	OR	0.47	0.26	0.86
1448589833	rs4673993	methotrexate	Efficacy	yes	Genotype CC is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.			= 0.01	OR	2.54	1.23	5.26
1445296571	rs10161126	alendronate	Efficacy	yes	Genotype GG is associated with increased response to alendronate in women with Bone Diseases as compared to genotypes AA + AG.	G		= 0.002	OR	2.06	1.08	6.41
1445296586	rs2032582	imatinib	Efficacy	yes	Allele C is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive.			= 0.031	OR	1.42	1.03	1.96
1449752734	rs1042522	oxaliplatin	Efficacy	yes	Genotypes CG + GG is associated with decreased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.	G		= 0.5	HR	0.87	0.57	1.32
1449752734	rs1042522	oxaliplatin	Efficacy	yes	Genotypes CG + GG is associated with decreased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.	G		= 0.58	HR	0.88	0.57	1.37
1445296591	rs1045642	imatinib	Efficacy	yes	Genotype GG is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.			= 0.011	OR	0.73	0.57	0.93
608431045	rs6280	clozapine	Efficacy	not stated	Allele T is not associated with response to clozapine in people with Schizophrenia as compared to allele C.			= 0.1	OR	0.82	0.65	1.04
1448262073	rs2284411	methylphenidate	Efficacy	yes	Genotype CC is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CT + TT.	C		= 0.026	OR	14.2	1.4	146.2
699639234	rs5443	sildenafil	Efficacy	yes	Genotype TT is associated with increased response to sildenafil in people with Erectile Dysfunction as compared to genotypes CC + CT.			= 0.01	OR	10.0	1.2	81.1
1448589644	rs1045642	methotrexate	Efficacy	yes	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.			= 0.01	OR	0.57	0.36	0.9
1447983413	rs1800544	methylphenidate	Efficacy	no	Allele G is associated with decreased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity as compared to allele C.			= 0.033	OR	0.56	0.329	0.953
981954002	rs2279287	lithium	Efficacy	no	Allele T is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.	T		= 0.57	OR	1.11		
981954014	rs1982350	lithium	Efficacy	no	Allele A is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele G.	A		= 0.86	OR	0.97		
981953971	rs1062613	clozapine	Efficacy	yes	Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele C.	T		= 0.02	OR	28.36	1.69	476.03
1450822078	rs1799971	ethanol	Dosage	yes	Genotypes AG + GG are associated with decreased dose of ethanol in women as compared to genotype AA.			= 0.049	OR	0.55	0.304	0.998
981954089	rs228697	lithium	Efficacy	no	Allele G is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.	G		= 0.66	OR	1.12		
981954083	rs228666	lithium	Efficacy	no	Allele C is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele T.	C		= 0.61	OR	0.92		
981954077	rs228642	lithium	Efficacy	no	Allele C is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele T.	C		= 0.58	OR	1.11		
1450822133	rs10485057	ethanol	Dosage	yes	Genotype AA is associated with increased dose of ethanol as compared to genotype AG.			= 0.001	OR	2.4	1.4	4.12
981954029	rs2278749	lithium	Efficacy	no	Allele T is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.	T		= 0.47	OR	1.18		
1449577002	rs17834628	salbutamol	Efficacy	yes	Allele A is associated with increased response to salbutamol in children with as compared to allele G.			= 1.18E-8	OR	1.67	1.29	2.16
981954051	rs34897046	lithium	Efficacy	no	Allele C is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele G.			= 0.45	OR	1.34		
981954045	rs3736544	lithium	Efficacy	no	Allele A is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele G.	A		= 0.1	OR	0.75		
1449577012	rs35661809	salbutamol	Efficacy	yes	Allele G is associated with increased response to salbutamol in children with as compared to allele A.			= 3.33E-8	OR	1.59	1.2	2.1
981954104	rs2640909	lithium	Efficacy	no	Allele C is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele T.	C		= 0.47	OR	0.88		
981954096	rs2859388	lithium	Efficacy	no	Allele G is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele A.	G		= 0.79	OR	1.05		
981954198	rs2276302	clozapine	Efficacy	yes	Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A.	G		= 0.02	OR	6.59	1.32	32.95
1450822299	rs16969968	nicotine	Efficacy	yes	Genotypes AA + AG are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype GG.			= 0.016	OR	10.0	1.54	65.1
1450822299	rs16969968	nicotine	Efficacy	yes	Genotypes AA + AG are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype GG.			= 0.028	OR	3.03	1.13	8.15
1449577151	rs9923231	warfarin	Efficacy	yes	Genotype CT is associated with decreased response to warfarin in people with Ventricular Dysfunction, Left as compared to genotype TT.	T	C	= 0.046	OR	4.89	1.02	36.45
1184168650	rs610604	ustekinumab	Efficacy	no	Genotype GG is not associated with response to ustekinumab in people with Psoriasis as compared to genotype TT.	G		= 0.75	OR	1.6		
1447675769	rs465646	cisplatin	Efficacy	no	Genotypes AG + GG are not associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype AA.	G		= 0.335	OR	1.5	0.66	3.44
1447675747	rs3087399	cisplatin	Efficacy	no	Genotypes CC + CT are not associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype TT.	C		= 0.707	OR	0.87	0.41	1.82
1447675754	rs3204953	cisplatin	Efficacy	no	Genotypes CT + TT are not associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype CC.	T		= 0.265	OR	1.56	0.71	3.51
1447675738	rs3087386	cisplatin	Efficacy	no	Genotypes AA + AG are not associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype GG.	A		= 0.189	OR	1.96	0.72	5.33
1447675704	rs3087403	cisplatin	Efficacy	yes	Genotypes CT + TT are associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype CC.	T		< 0.001	OR	4.44	1.92	10.27
1184168874	rs662	clopidogrel	Efficacy	no	Genotypes CC + CT is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype TT.	T		= 0.33	HR	0.92	0.62	1.37
1449167728	rs6700741	duloxetine	Efficacy	yes	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	0.16		
1449167736	rs4971678	duloxetine	Efficacy	yes	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.14		
1184168867	rs1045642	clopidogrel	Efficacy	no	Genotypes AA + AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	A		= 0.45	HR	1.17	0.78	1.78
1449167742	rs2933304	duloxetine	Efficacy	yes	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.			< 5E-5	OR	0.27		
1449167758	rs12630569	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	0.18		
1449167770	rs4334661	duloxetine	Efficacy	yes	Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	8.67		
1449167764	rs13093500	duloxetine	Efficacy	yes	Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	8.67		
1449167785	rs7616119	duloxetine	Efficacy	yes	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	8.67		
1450970060	rs1042028	tamoxifen	Efficacy	yes	Genotype TT is associated with decreased response to tamoxifen in women with Breast Neoplasms as compared to genotypes CC + CT.	T		= 0.004	HR	2.9	1.1	7.6
1450970060	rs1042028	tamoxifen	Efficacy	yes	Genotype TT is associated with decreased response to tamoxifen in women with Breast Neoplasms as compared to genotypes CC + CT.	T		= 0.45	HR	0.7	0.3	1.5
1449167791	rs7625956	duloxetine	Efficacy	yes	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	4.11		
1449167803	rs9310657	duloxetine	Efficacy	yes	Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.			< 5E-5	OR	8.67		
1449167797	rs7653345	duloxetine	Efficacy	yes	Allele A is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.			< 5E-5	OR	8.67		
1449167809	rs9310658	duloxetine	Efficacy	yes	Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	8.67		
1449167815	rs9819548	duloxetine	Efficacy	yes	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	8.67		
1449167827	rs9873889	duloxetine	Efficacy	yes	Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	4.63		
1449167821	rs9824595	duloxetine	Efficacy	yes	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	8.67		
1449167833	rs9879065	duloxetine	Efficacy	yes	Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	4.63		
769171199	rs1051266	methotrexate	Efficacy	yes	Allele T is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.			= 0.013	OR	1.78	1.13	2.81
1449167839	rs10007051	duloxetine	Efficacy	yes	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	0.29		
1449167845	rs11933890	duloxetine	Efficacy	yes	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.			< 5E-5	OR	0.3		
1449167857	rs55881666	duloxetine	Efficacy	yes	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	0.3		
1449167863	rs56229625	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	0.3		
1449167875	rs62319299	duloxetine	Efficacy	yes	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	0.3		
1449167869	rs61692318	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.15		
1449167881	rs10123866	duloxetine	Efficacy	yes	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	4.4		
1449167888	rs10124893	duloxetine	Efficacy	yes	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	4.19		
1449167894	rs10989064	duloxetine	Efficacy	yes	Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	4.4		
1449167900	rs6479008	duloxetine	Efficacy	yes	Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	4.4		
1449167912	rs7472	duloxetine	Efficacy	yes	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	4.4		
1450822736	rs1799971	nicotine	Other	no	Allele G is not associated with dose of nicotine in people with Tobacco Use Disorder as compared to allele A.			> 0.41	OR	0.8	0.4	1.59
1450822736	rs1799971	nicotine	Other	no	Allele G is not associated with dose of nicotine in people with Tobacco Use Disorder as compared to allele A.			> 0.41	OR	0.63	0.23	1.76
1450822736	rs1799971	nicotine	Other	no	Allele G is not associated with dose of nicotine in people with Tobacco Use Disorder as compared to allele A.			> 0.41	OR	0.63	0.21	1.89
1449167918	rs12595802	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.18		
982036564	rs1800206	fenofibrate	Efficacy	no	Allele C is not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to allele G.				OR	1.06	0.55	2.01
982036564	rs1800206	fenofibrate	Efficacy	no	Allele C is not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to allele G.				OR	1.3	0.64	2.62
1451134040	rs61734410	ethosuximide	Efficacy	yes	Allele T is associated with decreased clinical benefit to ethosuximide in children with Epilepsy as compared to allele C.	T	T	= 0.011	OR	2.63	1.25	5.56
1449167924	rs12603700	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.14		
1449167936	rs56355515	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.14		
1451134046	rs3747178	ethosuximide	Efficacy	yes	Allele T is associated with decreased clinical benefit to ethosuximide in children with Epilepsy as compared to allele C.	T	T	= 0.026	OR	2.38	1.11	5.0
1449167942	rs58042962	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.14		
1451134105	rs2753326	lamotrigine	Efficacy	yes	Allele A is associated with increased clinical benefit to lamotrigine in children with Epilepsy as compared to allele G.	A	A	= 0.038	OR	0.52	0.28	0.96
1448576460	rs1051266	methotrexate	Efficacy	yes	Genotype TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.			= 0.01	OR	1.91	1.16	3.15
1451134060	rs2032582	lamotrigine	Efficacy	yes	Allele A is associated with decreased clinical benefit to lamotrigine in children with Epilepsy as compared to allele C.	A	A	= 0.015	OR	2.22	1.16	4.17
1448576417	rs17602729	methotrexate	Efficacy	yes	Genotypes AA + AG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.			= 0.005	OR	1.77	1.19	2.63
1448576417	rs17602729	methotrexate	Efficacy	yes	Genotypes AA + AG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.			= 0.02	OR	1.82	1.08	3.07
1449168106	rs12094644	duloxetine	Efficacy	yes	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.27		
1449168100	rs12502866	duloxetine	Efficacy	yes	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	4.36		
1449168118	rs4437856	duloxetine	Efficacy	yes	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	0.27		
1449168131	rs4639250	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	0.3		
1449168125	rs12657120	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	0.31		
1449168137	rs13204353	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.32		
769170891	rs55754655	azathioprine	Efficacy	yes	Allele G is associated with decreased response to azathioprine in people with Inflammatory Bowel Diseases as compared to allele A.			= 0.035	OR	2.54	1.06	6.13
1449168143	rs9369266	duloxetine	Efficacy	yes	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.			< 5E-5	OR	0.31		
1449168155	rs3128624	duloxetine	Efficacy	yes	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.			< 5E-5	OR	0.32		
1449168149	rs3124955	duloxetine	Efficacy	yes	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	0.32		
1449168161	rs10771997	duloxetine	Efficacy	yes	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	0.17		
1449004322	rs2371108	glatiramer acetate	Efficacy	yes	Allele T is associated with increased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.	T	T	= 0.018	OR	2.34	1.39	3.96
1448592688	rs1801131	methotrexate	Efficacy	yes	Genotype GG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GT + TT.			= 0.04	OR	0.42	0.19	0.94
1449168167	rs10771998	duloxetine	Efficacy	yes	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.			< 5E-5	OR	0.17		
1449168173	rs7306991	duloxetine	Efficacy	yes	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	0.17		
1449168185	rs7316769	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	0.13		
1449004340	rs2114358	glatiramer acetate	Efficacy	yes	Allele A is associated with increased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.	A	A	= 0.045	OR	2.77	1.33	5.77
1449168191	rs17724452	duloxetine	Efficacy	yes	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.18		
1449168199	rs17724464	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	0.18		
1449168205	rs17724494	duloxetine	Efficacy	yes	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	0.18		
1449168233	rs61908402	duloxetine	Efficacy	yes	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	0.18		
1449168240	rs61908403	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.18		
1184136618	rs6759892	deferiprone	Efficacy	no	Genotype GG is not associated with response to deferiprone in people with beta-Thalassemia as compared to genotype TT.	G		= 0.6	OR	1.1	0.5	2.3
1184136611	rs2070959	deferiprone	Efficacy	yes	Genotype AA is associated with increased response to deferiprone in people with beta-Thalassemia as compared to genotype GG.	A		= 0.001	OR	4.6	1.65	12.8
1449168258	rs61908406	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.18		
1184136603	rs6759892	deferiprone	Efficacy	yes	Genotype GG is associated with increased response to deferiprone in people with beta-Thalassemia as compared to genotypes GT + TT.	G		= 0.04	OR	1.8	1.0	3.3
1184136590	rs2070959	deferiprone	Efficacy	yes	Genotype AA is associated with increased response to deferiprone in people with beta-Thalassemia as compared to genotypes AG + GG.	A		= 0.01	OR	3.1	1.2	8.3
1449168264	rs61908407	duloxetine	Efficacy	yes	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.			< 5E-5	OR	0.18		
1449168271	rs61908408	duloxetine	Efficacy	yes	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.			< 5E-5	OR	0.18		
1449168283	rs61908410	duloxetine	Efficacy	yes	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.18		
1449168277	rs61908409	duloxetine	Efficacy	yes	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.			< 5E-5	OR	0.18		
1449168289	rs61908411	duloxetine	Efficacy	yes	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	0.18		
1449168295	rs78482393	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.18		
1184988665	rs2160733	acamprosate	Efficacy	no	Allele C is not associated with response to acamprosate in people with Alcoholism as compared to allele A.	C	A	= 0.00065	HR	1.78		
1184988665	rs2160733	acamprosate	Efficacy	no	Allele C is not associated with response to acamprosate in people with Alcoholism as compared to allele A.	C	A	= 0.24	HR	0.76		
1449168301	rs78615940	duloxetine	Efficacy	yes	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	0.18		
1184988683	rs2160734	acamprosate	Efficacy	no	Allele C is not associated with response to acamprosate in people with Alcoholism as compared to allele T.	C	T	= 0.00079	HR	0.57		
1184988683	rs2160734	acamprosate	Efficacy	no	Allele C is not associated with response to acamprosate in people with Alcoholism as compared to allele T.	C	C	= 0.13	HR	1.31		
1451134380	rs2753325	lamotrigine	Efficacy	yes	Allele A is associated with increased clinical benefit to lamotrigine in children with Epilepsy as compared to allele G.	A	A	= 0.038	OR	0.52	0.28	0.96
769170633	rs1232027	methotrexate	Efficacy	yes	Allele A is associated with increased response to methotrexate in people with Arthritis, Psoriatic as compared to allele G.			= 0.02	OR	2.99	1.2	7.55
1184988627	rs2058878	acamprosate	Efficacy	yes	Allele A is associated with increased response to acamprosate in people with Alcoholism as compared to allele T.	A	T	= 0.024	HR	0.49		
1184988627	rs2058878	acamprosate	Efficacy	yes	Allele A is associated with increased response to acamprosate in people with Alcoholism as compared to allele T.	A	T	= 0.068	HR	0.72		
1184988646	rs17035723	acamprosate	Efficacy	no	Allele T is not associated with response to acamprosate in people with Alcoholism as compared to allele C.			= 0.000098	HR	2.88		
1184988646	rs17035723	acamprosate	Efficacy	no	Allele T is not associated with response to acamprosate in people with Alcoholism as compared to allele C.			= 0.00012	HR	2.14		
1184988646	rs17035723	acamprosate	Efficacy	no	Allele T is not associated with response to acamprosate in people with Alcoholism as compared to allele C.			= 0.48	HR	0.82		
1447674849	rs1570360	cetuximab	Efficacy	yes	Genotype GG is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes AA + AG.	A	A	= 0.015	OR	5.0	1.4	16.5
982035107	rs4253778	fenofibrate	Efficacy	yes	Genotype GG is associated with increased response to fenofibrate in people with Diabetes Mellitus as compared to genotypes CC + CG.			= 0.013	OR	3.19	1.28	7.92
1447674843	rs833061	cetuximab	Efficacy	yes	Genotype TT is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes CC + CT.	C	C	= 0.02	OR	10.0	1.2	100.0
1184513638	rs581111	buprenorphine	Efficacy	yes	Genotypes AA + AG is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype GG.			= 0.009	RR	1.56	1.41	1.78
1184513638	rs581111	buprenorphine	Efficacy	yes	Genotypes AA + AG is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype GG.			= 0.03	RR	1.67	1.06	2.1
1184513638	rs581111	buprenorphine	Efficacy	yes	Genotypes AA + AG is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype GG.			= 0.031	RR	1.72	1.25	1.97
1449004923	rs4244285	cyclophosphamide	Efficacy	yes	Genotypes AG + GG is associated with decreased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype AA.	G	G	= 0.0043	OR	2.69	1.36	5.32
1449004932	rs776746	cyclophosphamide	Efficacy	no	Genotype TT is associated with decreased response to cyclophosphamide in people with Lupus Nephritis as compared to genotypes CC + CT.	T	T	= 0.64	OR	0.76	0.31	31.85
1449004938	rs1695	cyclophosphamide	Efficacy	no	Genotypes AG + GG is associated with decreased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype AA.	G	G	= 0.03	OR	2.8	1.15	16.9
1447674471	rs1801131	methotrexate	Efficacy	yes	Genotypes GT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	G		= 0.02	OR	2.6	1.1	5.8
1185234906	rs1803274	rivastigmine	Efficacy	yes	Genotypes CT + TT is associated with decreased response to rivastigmine in people with Alzheimer Disease as compared to genotype CC.	C	T	= 0.016	OR	0.35	0.14	0.87
769169820	rs2246709	amlodipine	Efficacy	yes	Genotypes AG + GG are associated with increased response to amlodipine in people with Hypertension as compared to genotype AA.			= 0.01	HR	2.04	1.17	3.56
1450823878	rs1799971	nicotine	Other	yes	Genotypes AG + GG are associated with increased exposure to nicotine as compared to genotype GG.			= 0.00	OR	2.28	1.39	3.74
1450823878	rs1799971	nicotine	Other	yes	Genotypes AG + GG are associated with increased exposure to nicotine as compared to genotype GG.			= 0.51	OR	3.26	2.63	4.05
1450823878	rs1799971	nicotine	Other	yes	Genotypes AG + GG are associated with increased exposure to nicotine as compared to genotype GG.			= 0.97	OR	1.13	0.88	1.45
1446908186	rs121434568	erlotinib	Efficacy	yes	Allele G is associated with response to erlotinib in people with Carcinoma, Non-Small-Cell Lung.			= 0.001	HR	0.43	0.26	0.72
1446908186	rs121434568	erlotinib	Efficacy	yes	Allele G is associated with response to erlotinib in people with Carcinoma, Non-Small-Cell Lung.				HR	0.98	0.72	1.35
1184510363	rs396991	rituximab	Efficacy	yes	Genotype CC is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.	C		= 0.004	OR	9.43	2.08	42.7
1446908159	rs121434568	gefitinib	Efficacy	yes	Allele G is associated with response to gefitinib in people with Carcinoma, Non-Small-Cell Lung.			< 0.001	HR	0.34	0.24	0.49
1446908159	rs121434568	gefitinib	Efficacy	yes	Allele G is associated with response to gefitinib in people with Carcinoma, Non-Small-Cell Lung.				HR	1.14	0.85	1.52
1184510377	rs1061170	ranibizumab	Efficacy	no	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.			= 1.0	OR	0.79	0.43	1.43
1184510446	rs1136287	ranibizumab	Efficacy	no	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.			= 1.0	OR	1.13	0.64	1.97
1184510450	rs5888	ranibizumab	Efficacy	no	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.			= 1.0	OR	1.28	0.78	2.09
1449181636	rs1799971	naltrexone	Efficacy	yes	Genotypes AG + GG are associated with increased response to naltrexone in people with Alcoholism as compared to genotype AA.			= 0.03	OR	2.02	1.26	3.22
1448267876	rs2954625	metformin	Efficacy	yes	Genotypes CT + TT are associated with decreased response to metformin in people with Diabetes Mellitus as compared to genotype CC.			= 0.029	OR	0.23		
1184510386	rs3753394	ranibizumab	Efficacy	no	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.			= 1.0	OR	0.81	0.48	1.36
1184510390	rs1410996	ranibizumab	Efficacy	no	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.			= 0.847	OR	0.57	0.34	0.97
1184510394	rs1329428	ranibizumab	Efficacy	no	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.			= 0.281	OR	0.51	0.3	0.86
1184510398	rs10737680	ranibizumab	Efficacy	no	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele C.			= 1.0	OR	0.62	0.37	1.05
769169620	rs2290573	imatinib	Efficacy	yes	Genotype GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.			= 0.025	OR	6.72	1.51	29.91
1184510406	rs10490924	ranibizumab	Efficacy	no	Allele G is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.			= 1.0	OR	1.19	0.72	1.99
1184510410	rs11200638	ranibizumab	Efficacy	no	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.			= 1.0	OR	1.04	0.63	1.72
1184510414	rs429608	ranibizumab	Efficacy	no	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.			= 1.0	OR	1.5	0.64	3.48
1448267848	rs2617102	metformin	Efficacy	yes	Genotypes AC + CC is associated with decreased response to metformin in people with Diabetes Mellitus as compared to genotype AA.			= 0.02	OR	0.717		
1184510418	rs641153	ranibizumab	Efficacy	no	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.			= 1.0	OR	1.22	0.52	2.84
1184510422	rs9332739	ranibizumab	Efficacy	no	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.			= 1.0	OR	2.23	0.4	12.3
1184510426	rs10033900	ranibizumab	Efficacy	no	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.			= 1.0	OR	0.53	0.22	1.24
1184510430	rs3025039	ranibizumab	Efficacy	no	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.			= 1.0	OR	2.46	0.8	7.57
1184510434	rs699946	ranibizumab	Efficacy	no	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.			= 1.0	OR	1.25	0.74	2.13
1184510438	rs699947	ranibizumab	Efficacy	no	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele C.			= 0.166	OR	3.53	1.41	8.85
1448267827	rs316009	metformin	Efficacy	yes	Genotype TT is associated with increased response to metformin in people with Diabetes Mellitus as compared to genotypes CC + CT.			= 0.04	OR	1.21	1.11	1.31
1184510442	rs833061	ranibizumab	Efficacy	no	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.			= 0.198	OR	3.44	1.37	8.64
1450951310	rs3918290	fluorouracil	Efficacy	no	Genotype CT is not associated with response to fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	T		= 0.73	HR	1.12	0.58	2.17
827862175	rs2032582	atorvastatin	Efficacy	yes	Allele T is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to allele A.			= 0.022	OR	5.69	1.28	25.24
1451148002	rs933271	methadone	Efficacy	yes	Genotypes CC + CT are associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotype TT.	C		= 0.02	OR	1.53	1.06	2.2
827862165	rs2032582	atorvastatin	Efficacy	yes	Allele T is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to allele C.			= 0.022	OR	5.69	1.28	25.24
1449181943	rs8636	amisulpride	Efficacy	yes	Genotype CT is associated with increased response to amisulpride in people with Schizophrenia as compared to genotypes CC + TT.	C	C	= 0.027	OR	3.97	1.42	11.11
1449181943	rs8636	amisulpride	Efficacy	yes	Genotype CT is associated with increased response to amisulpride in people with Schizophrenia as compared to genotypes CC + TT.	C	C	= 0.053	OR	2.91	1.2	7.09
1451148012	rs737866	methadone	Efficacy	no	Allele C is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele T.	C		= 0.14	OR	0.79	0.56	1.08
1451148020	rs4680	methadone	Efficacy	no	Allele A is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele G.	A		= 0.73	OR	0.94	0.68	1.31
1444843357	rs246240	methotrexate	Efficacy	yes	Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.			= 0.008	OR	5.47	1.56	19.25
1444843366	rs3784864	methotrexate	Efficacy	yes	Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.			= 0.015	OR	4.24	1.32	13.65
1444843016	rs10305420	liraglutide	Efficacy	yes	Genotypes CT + TT are associated with decreased response to liraglutide in women with Obesity and Polycystic Ovary Syndrome as compared to genotype CC.	C	T	= 0.025	OR	0.27	0.09	0.85
981477479	rs1801133	methotrexate	Efficacy	no	Genotype GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid.	A		= 0.132	OR	2.73	1.03	7.26
1184166985	rs6822844	rituximab	Efficacy	yes	Genotype GG is associated with increased response to rituximab in people with Autoimmune Diseases as compared to genotype GT.	G	G	= 0.024	OR	3.53	1.06	11.64
1184166985	rs6822844	rituximab	Efficacy	yes	Genotype GG is associated with increased response to rituximab in people with Autoimmune Diseases as compared to genotype GT.	G	G	= 0.683	OR	1.0	0.02	10.67
1448594903	rs774359	ustekinumab	Efficacy	yes	Genotypes CC + CT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype TT.			= 0.016	OR	0.05	0.01	0.4
1449165982	rs17685420	methylphenidate	Efficacy	yes	Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 7.9E-05	OR	3.07	1.76	5.35
1449165990	rs3210967	methylphenidate	Efficacy	no	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 2.4E-03	OR	2.15	1.31	3.52
1449166003	rs2071421	methylphenidate	Efficacy	no	Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 7.71E-03	OR	2.63	1.29	5.37
1449165997	rs10413455	methylphenidate	Efficacy	no	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 5.7E-03	OR	4.93	1.59	15.3
1449166009	rs12302749	methylphenidate	Efficacy	no	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 8.48E-03	OR	1.91	1.18	3.09
1449166015	rs10420097	methylphenidate	Efficacy	no	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 9.13E-03	OR	4.98	1.49	16.6
1449166032	rs3810818	methylphenidate	Efficacy	no	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.019	OR	1.81	1.1	2.97
1444842903	rs6923761	liraglutide	Efficacy	no	Genotypes AA + AG are associated with increased response to liraglutide in women with Obesity and Polycystic Ovary Syndrome as compared to genotype GG.	A	G	= 0.058	OR	3.06	0.96	9.74
1449166050	rs9901675	methylphenidate	Efficacy	no	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.021	OR	2.95	1.18	7.39
1449166044	rs2886059	methylphenidate	Efficacy	no	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.020	OR	2.3	1.14	4.66
1449166057	rs4805162	methylphenidate	Efficacy	no	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.026	OR	1.72	1.07	2.76
1449166063	rs4562	methylphenidate	Efficacy	no	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.029	OR	1.65	1.05	2.59
1449166070	rs17712523	methylphenidate	Efficacy	no	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.031	OR	2.13	1.07	4.24
1449166082	rs12409352	methylphenidate	Efficacy	no	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.041	OR	2.15	1.03	4.49
1449166076	rs2799018	methylphenidate	Efficacy	no	Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.038	OR	1.67	1.03	2.71
1449166088	rs4902333	methylphenidate	Efficacy	no	Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.046	OR	1.68	1.01	2.98
1449166094	rs2295490	methylphenidate	Efficacy	no	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.048	OR	1.73	1.01	2.98
1449166106	rs1048786	methylphenidate	Efficacy	no	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.074	OR	2.03	0.93	4.43
1449166100	rs4627790	methylphenidate	Efficacy	no	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.060	OR	1.59	0.98	2.59
1449166112	rs9901673	methylphenidate	Efficacy	no	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.084	OR	1.82	0.92	3.59
1449166122	rs751655	methylphenidate	Efficacy	no	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.104	OR	1.76	0.89	3.49
1449166134	rs7858	methylphenidate	Efficacy	no	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.119	OR	1.78	0.86	3.67
1449166147	rs9032	methylphenidate	Efficacy	no	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.179	OR	1.52	0.82	2.81
1184511361	rs6295	fluoxetine	Efficacy	yes	Genotype CC is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to allele G.			= 0.009	OR	4.4	1.1	17.6
1449166140	rs929740	methylphenidate	Efficacy	no	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.169	OR	1.4	0.87	2.27
1184511472	rs9621532	ranibizumab	Efficacy	no	Genotype AA is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype AC.			= 1.0	OR	1.69	0.5	5.66
1449166275	rs1061735	methylphenidate	Efficacy	no	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.265	OR	1.46	0.75	2.84
1449166269	rs11552708	methylphenidate	Efficacy	no	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.207	OR	1.7	0.75	3.86
1449166319	rs11553441	methylphenidate	Efficacy	no	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.284	OR	1.46	0.73	2.9
1449166331	rs757978	methylphenidate	Efficacy	no	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.325	OR	1.59	0.63	4.01
1449166325	rs362272	methylphenidate	Efficacy	no	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.324	OR	1.34	0.75	2.41
1449166337	rs17279558	methylphenidate	Efficacy	no	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.348	OR	1.56	0.62	3.97
1449166351	rs1061115	methylphenidate	Efficacy	no	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.438	OR	1.22	0.74	2.02
1449166371	rs2013169	methylphenidate	Efficacy	no	Allele T is associated with decreased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.813	OR	0.92	0.46	1.84
1448594411	rs6311	ustekinumab	Efficacy	yes	Genotypes CT + TT is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype CC.			= 0.037	OR	20.04	1.32	303.34
1448594399	rs11591741	ustekinumab	Efficacy	yes	Genotypes CC + CG is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype GG.			= 0.029	OR	0.03	0.0	0.47
1448594392	rs191190	ustekinumab	Efficacy	yes	Genotypes CC + CT is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype TT.			= 0.037	OR	28.29	1.64	513.06
827813351	rs45445694	fluorouracil	Efficacy	yes	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with decreased response to fluorouracil in people with Colorectal Neoplasms.			= 0.001	HR	1.89	1.29	2.7
827813351	rs45445694	fluorouracil	Efficacy	yes	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with decreased response to fluorouracil in people with Colorectal Neoplasms.			= 0.004	HR	2.65	1.4	4.75
827813351	rs45445694	fluorouracil	Efficacy	yes	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with decreased response to fluorouracil in people with Colorectal Neoplasms.			= 0.03	HR	1.69	1.03	2.66
1448594141	rs1128503	imatinib	Efficacy	no	Allele G is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.			= 0.847	OR	1.025	0.795	1.322
1448594134	rs1045642	imatinib	Efficacy	no	Allele G is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.			= 0.454	OR	1.096	0.862	1.392
1448594125	rs2231142	imatinib	Efficacy	yes	Allele T is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.			= 0.000	OR	0.556	0.41	0.752
1448594125	rs2231142	imatinib	Efficacy	yes	Allele T is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.			= 0.025	OR	0.646	0.441	0.946
1448594125	rs2231142	imatinib	Efficacy	yes	Allele T is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.			= 0.033	OR	0.707	0.514	0.972
1448594125	rs2231142	imatinib	Efficacy	yes	Allele T is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.			= 0.352	OR	0.831	0.564	1.226
1448594115	rs2032582	imatinib	Efficacy	yes	Genotypes AT + TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.			= 0.020	OR	0.632	0.43	0.929
1448594115	rs2032582	imatinib	Efficacy	yes	Genotypes AT + TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.			= 0.037	OR	0.653	0.437	0.975
1449002901	rs4149056	methotrexate	Efficacy	yes	Genotype CC is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.			< 0.001	HR	12.242	3.937	38.059
1449576353	rs1799836	levodopa	Dosage	no	Genotype CT is not associated with dose of levodopa in women with Parkinson Disease as compared to genotype CC.	T		= 0.17	OR	2.4	0.8	7.0
1449002928	rs2838958	methotrexate	Efficacy	yes	Genotype AA is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.			= 0.019	HR	2.342	1.147	4.71
1449576366	rs4680	levodopa	Dosage	no	Genotype AG is not associated with dose of levodopa in people with Parkinson Disease as compared to genotype GG.	A		= 0.43	OR	0.7	0.4	1.4
1449576387	rs1799836	levodopa	Dosage	no	Allele C is not associated with dose of levodopa in men with Parkinson Disease as compared to allele T.	T		= 0.63	OR	1.5	0.3	6.0
1184512008	rs2274567	eculizumab	Efficacy	yes	Genotypes AG + GG is associated with decreased response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype AA.	A		= 0.012	OR	2.7	1.2	6.2
1184512008	rs2274567	eculizumab	Efficacy	yes	Genotypes AG + GG is associated with decreased response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype AA.	A		= 0.012	OR	7.26	1.4	38.8
1184512015	rs3811381	eculizumab	Efficacy	no	Genotypes CG + GG is not associated with response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype CC.	C		= 0.054	OR	2.1	0.9	4.6
1184512015	rs3811381	eculizumab	Efficacy	no	Genotypes CG + GG is not associated with response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype CC.	C		= 0.054	OR	4.4	0.9	21.6
1184512020	rs2230199	eculizumab	Efficacy	no	Genotypes CC + CG is not associated with response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype GG.	C		= 0.934	OR	1.0	0.4	2.4
1184512020	rs2230199	eculizumab	Efficacy	no	Genotypes CC + CG is not associated with response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype GG.	C		= 0.934	OR	1.0	0.2	5.9
1448266309	rs7703002	platinum	Efficacy	no	Genotype AA is associated with decreased response to platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.			= 0.029	OR	2.73	1.16	6.46
1447676481	rs763780	infliximab	Efficacy	yes	Genotype CT is associated with increased response to infliximab in people with Psoriasis as compared to genotype TT.	C		= 0.023	OR	0.0		
1448266301	rs7719775	platinum	Efficacy	no	Genotype AA is associated with decreased response to platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.			= 0.013	OR	1.82	1.15	2.86
1447676470	rs763780	ustekinumab	Efficacy	yes	Genotype TT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CT.	C		= 0.016	OR	14.18	1.35	149.42
1447676470	rs763780	ustekinumab	Efficacy	yes	Genotype TT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CT.	C		= 0.022	OR	12.23	1.17	127.36
1448266279	rs6878291	platinum	Efficacy	yes	Genotype GG is associated with decreased response to platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	G	G	= 0.001	OR	2.04	1.35	3.07
1448102401	rs4291	sertraline	Efficacy	no	Genotype TT is not associated with response to sertraline in people with Depressive Disorder.	T	T	= 0.803	OR	1.41	0.84	2.53
1450821690	rs11280056	fluorouracil	Efficacy	yes	Genotype TTAAAGTTA/del is associated with decreased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del.			= 0.001	HR	1.89	1.29	2.7
1450821690	rs11280056	fluorouracil	Efficacy	yes	Genotype TTAAAGTTA/del is associated with decreased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del.			= 0.004	HR	2.65	1.4	4.65
1450821690	rs11280056	fluorouracil	Efficacy	yes	Genotype TTAAAGTTA/del is associated with decreased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del.			= 0.03	HR	1.69	1.03	2.66
1450936460	rs28362731	cisplatin	Efficacy	no	Genotype AG is not associated with response to cisplatin in people with Mesothelioma as compared to genotype GG.			= 0.130	HR	0.56	0.26	1.19
1450936460	rs28362731	cisplatin	Efficacy	no	Genotype AG is not associated with response to cisplatin in people with Mesothelioma as compared to genotype GG.			= 0.299	HR	0.72	0.39	1.33
1450936460	rs28362731	cisplatin	Efficacy	no	Genotype AG is not associated with response to cisplatin in people with Mesothelioma as compared to genotype GG.			= 0.481	HR	1.56	0.46	5.31
1448266217	rs12995526	methotrexate	Efficacy	yes	Genotypes CT + TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	C	C	= 0.001	OR	0.23	0.1	0.53
827698919	rs3918242	Methyldopa	Efficacy	yes	Genotypes CT + TT are associated with decreased response to Methyldopa in people with Gestational hypertension as compared to genotype CC.			= 0.036	OR	2.23	1.06	4.73
1450936468	rs1049305	cisplatin	Efficacy	no	Genotypes CC + CG are not associated with response to cisplatin in people with Mesothelioma as compared to genotype GG.			= 0.220	HR	0.81	0.58	1.14
1450936468	rs1049305	cisplatin	Efficacy	no	Genotypes CC + CG are not associated with response to cisplatin in people with Mesothelioma as compared to genotype GG.			= 0.233	HR	0.83	0.62	1.13
1450936468	rs1049305	cisplatin	Efficacy	no	Genotypes CC + CG are not associated with response to cisplatin in people with Mesothelioma as compared to genotype GG.			= 0.810	HR	1.08	0.59	1.97
1448266210	rs7563206	methotrexate	Efficacy	yes	Genotypes CT + TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	C	C	< 0.001	OR	0.2	0.09	0.46
1448266196	rs2372536	methotrexate	Efficacy	yes	Genotypes CC + CG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	C	C	= 0.036	OR	0.27	0.08	0.92
1448266203	rs4673993	methotrexate	Efficacy	yes	Genotypes CT + TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	C	C	= 0.036	OR	0.27	0.08	0.92
1448266186	rs1801394	methotrexate	Efficacy	yes	Genotypes AA + AG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	A	A	= 0.041	OR	2.16	1.03	4.53
1448102319	rs1799752	sertraline	Efficacy	yes	Genotype del/del is associated with increased response to sertraline in people with Depressive Disorder.	del	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	= 0.0006	OR	3.03	1.08	5.08
1448102319	rs1799752	sertraline	Efficacy	yes	Genotype del/del is associated with increased response to sertraline in people with Depressive Disorder.			= 0.006	OR	3.7	1.66	8.29
1448266150	rs1805087	methotrexate	Efficacy	yes	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	A	A	= 0.017	OR	0.42	0.2	0.86
1448266111	rs1801133	methotrexate	Efficacy	yes	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	A	A	= 0.019	OR	3.86	1.25	11.89
1447987564	rs4646	tamoxifen	Efficacy	yes	Genotypes AA + AC are associated with increased response to tamoxifen in women with Breast Neoplasms as compared to genotype CC.	A		= 0.011	HR	0.681	0.506	0.917
1448266104	rs1801131	methotrexate	Efficacy	yes	Genotype TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + GT.	T	T	= 0.045	OR	0.51	0.26	0.98
1447676212	rs9904341	methotrexate	Efficacy	yes	Genotype CG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	C		= 0.046	OR	2.34	1.02	5.38
827864092	rs1801058	metoprolol	Efficacy	no	Genotype CT is not associated with decreased response to metoprolol in men with hypertensive nephrosclerosis as compared to genotype CC.	T		= 0.25	HR	0.66	0.33	1.34
1449154881	rs887829	atazanavir	Toxicity	yes	Genotype TT is associated with increased discontinuation of atazanavir as compared to genotype CC.			= 0.026	HR	9.4	1.3	66.9
1449154881	rs887829	atazanavir	Toxicity	yes	Genotype TT is associated with increased discontinuation of atazanavir as compared to genotype CC.			= 0.038	HR	5.2	1.1	24.5
1449154896	rs887829	atazanavir	Toxicity	no	Genotype TT is not associated with increased discontinuation of atazanavir as compared to genotype CC.			= 0.45	HR	0.3	0.01	6.7
1449154902	rs887829	atazanavir	Toxicity	no	Genotype CT is not associated with increased discontinuation of atazanavir as compared to genotype CC.			= 0.3	HR	1.5	0.5	8.4
1449154902	rs887829	atazanavir	Toxicity	no	Genotype CT is not associated with increased discontinuation of atazanavir as compared to genotype CC.			= 0.77	HR	1.4	0.1	13.6
1449154902	rs887829	atazanavir	Toxicity	no	Genotype CT is not associated with increased discontinuation of atazanavir as compared to genotype CC.			= 0.78	HR	1.3	0.2	9.4
827864047	rs1024323	metoprolol	Efficacy	yes	Genotype CC is associated with decreased response to metoprolol in men with hypertensive nephrosclerosis as compared to genotype TT.			= 0.001	HR	2.14	1.35	3.39
827864047	rs1024323	metoprolol	Efficacy	yes	Genotype CC is associated with decreased response to metoprolol in men with hypertensive nephrosclerosis as compared to genotype TT.	T		= 0.009	HR	1.54	1.11	2.44
827864047	rs1024323	metoprolol	Efficacy	yes	Genotype CC is associated with decreased response to metoprolol in men with hypertensive nephrosclerosis as compared to genotype TT.			= 0.01	HR	2.24	1.2	4.18
827864047	rs1024323	metoprolol	Efficacy	yes	Genotype CC is associated with decreased response to metoprolol in men with hypertensive nephrosclerosis as compared to genotype TT.			= 0.31	HR	1.99	0.52	7.57
1449154934	rs1801274	cetuximab	Efficacy	yes	Genotype GG is associated with increased response to cetuximab in people with Head and Neck Neoplasms as compared to genotypes AA + AG.	A		= 0.02	HR	1.71	1.11	2.65
1449154943	rs396991	cetuximab	Efficacy	yes	Genotype AA is associated with increased response to cetuximab in people with Head and Neck Neoplasms as compared to genotypes AC + CC.	A		= 0.02	HR	1.71	1.11	2.65
1451104640	rs3781719	botulinum toxin type a	Efficacy	yes	Allele G is associated with decreased response to botulinum toxin type a in women with Migraine NOS as compared to allele A.	G	G	= 0.029	OR	1.88	1.06	3.32
981794238	rs9394992	gemcitabine	Efficacy	no	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	T		= 0.704	HR	1.08	0.74	1.57
1450973680	rs429358	ranibizumab	Efficacy	no	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.			= 1.0	OR	1.9	0.94	3.81
1447679904	rs396991	rituximab	Efficacy	yes	Genotype AA is associated with decreased response to rituximab in people with Neuromyelitis Optica as compared to genotype CC.	A		= 0.03	OR	24.87	2.0	1027.54
1450826481	rs28363170	ethanol	Toxicity	yes	Allele del is associated with increased exposure to ethanol in healthy individuals as compared to allele GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT.	del		< 0.001	OR	1.356	1.222	1.503
1450826481	rs28363170	ethanol	Toxicity	yes	Allele del is associated with increased exposure to ethanol in healthy individuals as compared to allele GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT.	del		= 0.068	OR	0.804	0.637	1.016
1450826481	rs28363170	ethanol	Toxicity	yes	Allele del is associated with increased exposure to ethanol in healthy individuals as compared to allele GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT.	del		= 0.174	OR	1.185	0.928	1.512
1450826488	rs1799971	ethanol	Toxicity	yes	Genotypes AG + GG is associated with decreased exposure to ethanol in healthy individuals as compared to genotype AA.	G		< 0.001	OR	0.545	0.415	0.715
1450826488	rs1799971	ethanol	Toxicity	yes	Genotypes AG + GG is associated with decreased exposure to ethanol in healthy individuals as compared to genotype AA.	G		= 0.110	OR	0.913	0.817	1.021
1450826488	rs1799971	ethanol	Toxicity	yes	Genotypes AG + GG is associated with decreased exposure to ethanol in healthy individuals as compared to genotype AA.	G		= 0.375	OR	0.891	0.689	1.151
827864125	rs2960306	metoprolol	Efficacy	no	Genotype TT is not associated with decreased response to metoprolol in women with hypertensive nephrosclerosis as compared to genotype GG.			= 0.21	HR	0.72	0.44	1.2
827864109	rs1801058	metoprolol	Efficacy	yes	Genotype CT is associated with decreased response to metoprolol in women with hypertensive nephrosclerosis as compared to genotype CC.			= 0.05	HR	0.46	0.21	1.0
1449155460	rs5744174	ustekinumab	Efficacy	yes	Genotypes AG + GG is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype AA.	A		= 0.0012	OR	5.26	1.93	14.38
981237722	rs1044457	gemcitabine	Efficacy	yes	Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.			= 0.001	HR	1.84	1.28	2.66
981237722	rs1044457	gemcitabine	Efficacy	yes	Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.			= 0.002	HR	1.9	1.26	2.87
1449188291	rs1043550	acenocoumarol	Dosage	yes	Allele G is associated with increased dose of acenocoumarol in people with Atrial Fibrillation as compared to allele A.			= 0.009	OR	3.96	1.41	11.09
1449188284	rs2108622	acenocoumarol	Dosage	yes	Allele T is associated with increased dose of acenocoumarol in people with Atrial Fibrillation as compared to allele C.			= 0.047	OR	3.12	1.01	9.63
1449270232	rs1045642	methotrexate	Efficacy	yes	Genotype AA is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.				OR	2.21	1.23	3.97
1449270224	rs1801133	methotrexate	Efficacy	yes	Genotype AA is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.				OR	0.4	0.19	0.84
1449270251	rs12231740	methotrexate	Efficacy	yes	Allele T is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele C.				OR	0.63	0.43	0.93
1449270240	rs1128503	methotrexate	Efficacy	yes	Genotype AA is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.				OR	2.23	1.35	3.69
981237777	rs12507552	gemcitabine	Efficacy	yes	Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.			< 0.001	HR	2.53	1.51	4.25
981237781	rs3778504	gemcitabine	Efficacy	no	Genotypes AA + AG are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype GG.			= 0.208	HR	0.56	0.23	1.38
1449270257	rs3763980	methotrexate	Efficacy	yes	Allele A is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T.				OR	0.53	0.35	0.8
1445402159	rs2072660	varenicline	Efficacy	no	Genotypes CT + TT are not associated with response to varenicline in people with Tobacco Use Disorder as compared to genotype CC.			= 0.66	OR	1.01	0.97	1.05
1449270277	rs1801394	methotrexate	Efficacy	yes	Genotypes AG + GG is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype AA.				OR	2.19	1.01	4.76
981237788	rs274713	gemcitabine	Efficacy	yes	Genotype GG is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.			= 0.031	HR	1.49	1.04	2.15
981237795	rs274717	gemcitabine	Efficacy	no	Genotypes AG + GG are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.			= 0.05	HR	0.71	0.5	1.0
1450367980	rs5333	prednisone	Efficacy	yes	Genotypes CC + CT is associated with increased resistance to prednisone in children with Nephrotic Syndrome as compared to genotype TT.	C	C	= 0.016	OR	2.74	1.2	6.27
981237802	rs992160	gemcitabine	Efficacy	yes	Genotypes CT + TT are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.			= 0.039	HR	0.49	0.25	0.96
981237767	rs35687416	gemcitabine	Efficacy	yes	Genotype GG is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.			= 0.001	HR	2.41	1.39	4.18
981237767	rs35687416	gemcitabine	Efficacy	yes	Genotype GG is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.			= 0.011	HR	1.94	1.16	3.24
981237838	rs944050	gemcitabine	Efficacy	yes	Genotype TT is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CC + CT.			= 0.002	HR	1.72	1.21	2.43
1448613393	rs6809699	clopidogrel	Efficacy	yes	Genotypes AA + AC is associated with increased resistance to clopidogrel as compared to genotype CC.			= 0.001	OR	3.68	1.71	7.92
981237807	rs10916852	gemcitabine	Efficacy	yes	Genotypes GT + TT are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype GG.			= 0.028	HR	0.57	0.35	0.94
1445402137	rs2236196	varenicline	Efficacy	no	Genotypes AA + AG is not associated with response to varenicline in people with Tobacco Use Disorder as compared to genotype GG.			= 0.66	OR	1.15	0.61	2.17
981237814	rs3925058	gemcitabine	Efficacy	no	Genotype AA is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.			= 0.059	HR	1.38	0.99	1.94
1448613376	rs6785930	clopidogrel	Efficacy	yes	Genotypes AA + AG is associated with increased resistance to clopidogrel as compared to genotype GG.			= 0.002	OR	2.89	1.48	5.64
981237819	rs7543016	gemcitabine	Efficacy	yes	Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CG + GG.			= 0.047	HR	1.41	1.0	1.97
1445402071	rs1044396	varenicline	Efficacy	yes	Genotype GG is associated with decreased response to varenicline in people with Tobacco Use Disorder as compared to genotypes AA + AG.			= 0.02	OR	1.67	1.1	2.53
1449270432	rs1495741	iguratimod	Efficacy	yes	Genotypes AG + GG is associated with decreased clinical benefit to iguratimod in people with Arthritis, Rheumatoid as compared to genotype AA.	G	G	= 0.039	OR	0.498	0.256	0.967
1449270454	rs2032582	iguratimod	Efficacy	yes	Genotypes CT + TT is associated with increased clinical benefit to iguratimod in people with Arthritis, Rheumatoid as compared to genotype CC.	T	T	= 0.023	OR	2.041	1.093	3.811
1449270444	rs2231142	iguratimod	Efficacy	yes	Genotypes GT + TT is associated with increased clinical benefit to iguratimod in people with Arthritis, Rheumatoid as compared to genotype GG.	T	T	= 0.038	OR	1.944	1.038	3.641
981483776	rs7787082	clozapine	Efficacy	yes	Allele G is associated with decreased response to clozapine in people with Schizophrenia as compared to allele A.	A		= 0.036	OR	4.87	1.78	13.3
981483784	rs10248420	clozapine	Efficacy	yes	Allele A is associated with decreased response to clozapine in people with Schizophrenia as compared to allele G.	A		= 0.046	OR	4.1	1.59	10.55
1184165220	rs3785143	atomoxetine	Efficacy	yes	Allele T is associated with decreased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.			= 0.0048	OR	2.66	1.35	5.26
1451138662	rs3802281	methadone	Dosage	yes	Genotype TT is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes CC + CT.	C		= 0.024	OR	0.574	0.354	0.931
1451138607	rs3802279	methadone	Dosage	yes	Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes CT + TT.	T		= 0.024	OR	0.574	0.354	0.931
1451138701	rs16918842	methadone	Dosage	no	Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele C.	T		= 0.088	OR	0.615	0.359	1.053
1451138721	rs3808627	methadone	Dosage	no	Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele C.	T		= 0.364	OR	1.13	0.868	1.47
1448432602	rs2372536	methotrexate	Efficacy	yes	Genotype GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.	G	G	= 0.005	OR	2.4	1.3	4.42
1451138668	rs963549	methadone	Dosage	yes	Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes CT + TT.	T		= 0.031	OR	0.586	0.361	0.952
1446695874	rs2305948	sunitinib	Efficacy	no	Genotype CT is not associated with response to sunitinib in people with Carcinoma, Renal Cell as compared to genotype CC.	T	C	= 0.16	OR	0.5	0.2	1.3
1451138764	rs3802281	heroin	Dosage	no	Allele C is not associated with dose of heroin in people with Heroin Dependence as compared to allele T.	C		= 0.500	OR	0.875	0.595	1.289
1451138773	rs3808627	heroin	Dosage	no	Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele C.	T		= 0.512	OR	1.082	0.855	1.368
1451138786	rs16918842	heroin	Dosage	no	Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele C.	T		= 0.675	OR	0.909	0.583	1.418
1451138781	rs963549	heroin	Dosage	no	Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele C.	T		= 0.547	OR	0.887	0.599	1.312
1451138791	rs12205732	heroin	Dosage	no	Allele A is not associated with dose of heroin in people with Heroin Dependence as compared to allele G.	A		= 0.797	OR	0.958	0.693	1.325
1451138747	rs6912029	methadone	Dosage	no	Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele G.	T		= 0.208	OR	1.258	0.879	1.801
1451138741	rs12205732	methadone	Dosage	no	Allele A is not associated with dose of methadone in people with Heroin Dependence as compared to allele G.	A		= 0.237	OR	1.242	0.867	1.78
1451138753	rs9322453	methadone	Dosage	no	Allele C is not associated with dose of methadone in people with Heroin Dependence as compared to allele G.	C		= 0.412	OR	0.905	0.714	1.148
1451138759	rs3802279	heroin	Dosage	no	Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele C.	T		= 0.500	OR	0.875	0.595	1.289
1448612701	rs1045642	imatinib	Efficacy	yes	Genotype AA is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.			= 0.005	OR	0.309	0.134	0.708
1451138802	rs9322453	heroin	Dosage	no	Allele C is not associated with dose of heroin in people with Heroin Dependence as compared to allele G.	C		= 0.181	OR	0.865	0.7	1.069
1451138797	rs6912029	heroin	Dosage	no	Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele G.	T		= 0.778	OR	0.955	0.692	1.318
981859123	rs9606186	risperidone	Efficacy	yes	Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.			= 0.02	OR	3.95		
982006735	rs9923231	acenocoumarol	Dosage	yes	Genotype CT is associated with decreased dose of acenocoumarol as compared to genotype CC.	T		< 0.001	OR	6.5	1.38	30.5
1451106280	rs9828223	adalimumab	Efficacy	yes	Allele T is associated with decreased response to adalimumab in people with Crohn Disease as compared to allele C.	T		= 1.88E-9	OR	20.2	5.57	73.27
1451106280	rs9828223	adalimumab	Efficacy	yes	Allele T is associated with decreased response to adalimumab in people with Crohn Disease as compared to allele C.			= 0.019	OR	1.77	1.09	5.02
1451106280	rs9828223	adalimumab	Efficacy	yes	Allele T is associated with decreased response to adalimumab in people with Crohn Disease as compared to allele C.	T		= 0.044	OR	1.16	1.09	1.23
982006724	rs9923231	acenocoumarol	Dosage	yes	Genotype TT is associated with decreased dose of acenocoumarol as compared to genotypes CC + CT.	T		< 0.001	OR	11.6	2.26	59.58
982006874	rs1967554	methadone	Efficacy	yes	Allele C is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A.			= 0.011	OR	20.25	1.46	280.5
1447678493	rs1045642	carbamazepine	Efficacy	no	Genotype GG is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes AA + AG.	G	A	= 0.91	OR	1.06	0.421	2.643
1450811473	rs1045280	nicotine	Efficacy	no	Allele C is not associated with response to nicotine in people with Tobacco Use Disorder as compared to allele T.	C		= 0.45	OR	0.84	0.54	1.32
1450811473	rs1045280	nicotine	Efficacy	no	Allele C is not associated with response to nicotine in people with Tobacco Use Disorder as compared to allele T.	C		= 0.69	OR	1.14	0.61	2.13
1447678481	rs3812718	carbamazepine	Efficacy	no	Genotype CC is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	C	T	= 0.97	OR	0.47	2.045	
1450811453	rs3852209	nicotine	Efficacy	yes	Genotypes CT + TT are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype CC.	T		= 0.013	OR	1.96	1.16	3.34
1450811453	rs3852209	nicotine	Efficacy	yes	Genotypes CT + TT are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype CC.	T		= 0.099	OR	1.46	0.93	2.28
1447678447	rs2234922	carbamazepine	Efficacy	no	Genotype AA is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes AG + GG.	A	G	= 0.79	OR	1.05	0.543	2.228
982006849	rs7127507	methadone	Efficacy	yes	Allele C is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele T.			= 0.011	OR	20.25	1.46	280.5
981793945	rs2072671	gemcitabine	Efficacy	yes	Genotype AA is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AC + CC.	C		= 0.017	OR	2.5	1.18	5.28
982006932	rs11030119	methadone	Efficacy	yes	Allele G is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A.			= 0.011	OR	20.25	1.46	280.5
1447678435	rs1051740	carbamazepine	Efficacy	no	Genotype TT is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	C	T	= 0.97	OR	0.98	0.47	2.045
982006898	rs11030118	methadone	Efficacy	yes	Allele G is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A.			= 0.011	OR	20.25	1.46	280.5
982006921	rs2030324	methadone	Efficacy	yes	Allele G is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A.			= 0.011	OR	20.25	1.46	280.5
982006910	rs988748	methadone	Efficacy	yes	Allele C is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele G.			= 0.011	OR	20.25	1.46	280.5
981793996	rs9937	gemcitabine	Efficacy	yes	Genotype AA is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.	G		= 0.048	HR	1.53	1.0	2.34
981793968	rs4694362	gemcitabine	Efficacy	no	Genotype TT is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	T		= 0.653	HR	0.92	0.64	1.32
1450811579	rs1128503	methadone	Dosage	yes	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.	A	A	= 0.0325	OR	6.66	1.41	31.36
1449005428	rs1128503	imatinib	Efficacy	no	Allele A is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.			= 0.12	OR	0.66	0.29	1.45
1449005441	rs1045642	imatinib	Efficacy	no	Allele A is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.	G	A	= 0.21	OR	0.62	0.28	1.34
1183703531	rs1050152	imatinib	Efficacy	yes	Genotype TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.	T		= 0.03	HR	0.79	0.63	0.98
1183703589	rs1045642	imatinib	Efficacy	yes	Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.	A		= 0.005	HR	0.56	0.37	0.84
1183703569	rs2282143	imatinib	Efficacy	no	Genotype CC is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CT + TT.	T		= 0.08	HR	0.25	0.03	1.79
1183703573	rs1045642	imatinib	Efficacy	no	Genotype GG is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	A		= 0.09	HR	0.79	0.6	1.04
1183703560	rs1050152	imatinib	Efficacy	no	Genotype TT is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.	T		= 0.06	HR	0.81	0.65	1.01
1183703536	rs3213619	imatinib	Efficacy	no	Genotype AA is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.	G		= 0.06	HR	1.92	1.03	3.56
1183703536	rs3213619	imatinib	Efficacy	no	Genotype AA is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.	G		= 0.07	HR	2.27	1.03	5.0
1183703536	rs3213619	imatinib	Efficacy	no	Genotype AA is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.	G		= 0.07	HR	1.85	0.99	3.44
1183703546	rs2282143	imatinib	Efficacy	no	Genotype CC is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CT + TT.	T		= 0.05	HR	1.87	1.06	3.29
1183703542	rs1045642	imatinib	Efficacy	no	Genotype GG is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	A		= 0.06	HR	0.7	0.49	1.02
1446895600	rs2299214	risperidone	Efficacy	yes	Genotypes CC + CT is associated with decreased response to risperidone in people with Schizophrenia as compared to genotype TT.			= 0.039	OR	2.25	1.04	4.87
1183703603	rs1050152	imatinib	Efficacy	yes	Genotype TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.	T		= 0.03	HR	0.77	0.61	0.97
1183703597	rs3213619	imatinib	Efficacy	no	Genotype AA is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.	G		= 0.08	HR	2.78	1.01	8.02
1183703611	rs2740574	imatinib	Efficacy	no	Genotypes CT + TT is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC.	C		= 0.07	HR	1.78	1.0	3.17
1183703607	rs1050152	imatinib	Efficacy	no	Genotype TT is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.	T		= 0.07	HR	0.7	0.48	1.03
1444929453	rs2053044	ramipril	Efficacy	yes	Genotypes AA + AG is associated with increased response to ramipril in people with Hypertension as compared to genotype GG.			< 0.05	HR	2.09	1.21	3.6
1446748136	rs2032582	sunitinib	Efficacy	yes	Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell.			= 0.005	HR	5.0	1.6	15.2
1446748136	rs2032582	sunitinib	Efficacy	yes	Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell.	A		= 0.01	OR	0.1	0.0	0.6
1446748136	rs2032582	sunitinib	Efficacy	yes	Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell.	A		= 0.12	HR	2.0	0.8	5.0
1446748136	rs2032582	sunitinib	Efficacy	yes	Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell.	A		= 0.44	HR	1.5	0.5	4.7
1449169755	rs717620	atorvastatin	Efficacy	yes	Genotypes CT + TT are associated with decreased response to atorvastatin in men with Hypercholesterolemia as compared to genotype CC.			= 0.020	OR	4.609	1.27	16.72
1444667028	rs1063538	pioglitazone	Efficacy	no	Genotypes CC + CT are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype TT.	C	T	= 0.765	OR	1.255	0.283	5.62
1444666932	rs266729	pioglitazone	Efficacy	no	Genotype CC are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotypes CG + GG.	G	C	= 0.856	OR	1.219	0.156	9.352
1444666944	rs16861194	pioglitazone	Efficacy	no	Genotype AG are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype AA.	G	A	= 0.781	OR	1.274	0.231	7.019
1444666960	rs1063537	pioglitazone	Efficacy	no	Genotype CC are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotypes CT + TT.	C	T	= 0.235	OR	2.972	0.492	17.947
1444666966	rs2082940	pioglitazone	Efficacy	no	Genotype CC are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotypes CT + TT.	C	T	= 0.719	OR	1.303	0.308	5.515
1450415126	rs1045642	methotrexate	Efficacy	yes	Genotype GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.			= 0.047	OR	1.35	1.01	1.82
1448107552	rs776746	rosuvastatin	Efficacy	yes	Allele C is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele T.			= 0.017	OR	2.289	1.157	4.527
1444666874	rs1501299	pioglitazone	Efficacy	no	Genotypes GT + TT are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype TT.	G	T	= 0.461	OR	1.718	0.408	7.23
1449645155	rs316019	metformin	Efficacy	yes	Genotypes AA + AC is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	A	A	= 0.0064	OR	0.35	0.16	0.77
1450415186	rs293983	belimumab	Efficacy	no	Allele T is not associated with response to belimumab in people with Lupus erythematosus as compared to allele C.			= 0.64	OR	0.9	0.52	1.57
827816679	rs2107506	lithium	Efficacy	no	Allele C is not associated with response to lithium in people with Bipolar Disorder as compared to allele G.	C	C	= 0.2208	OR	1.27	0.82	1.95
1448107497	rs2231142	rosuvastatin	Efficacy	yes	Allele T is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele G.			= 0.017	OR	2.289	1.157	4.527
1449645164	rs12943590	metformin	Efficacy	yes	Genotypes AA + AG is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	A	A	= 0.19	OR	0.68	0.38	1.22
1448615387	rs34231037	sunitinib	Efficacy	no	Genotype AG is associated with response to sunitinib as compared to genotype GG.			= 0.062	OR	2.58	0.95	6.99
1444666816	rs2241766	pioglitazone	Efficacy	yes	Genotype GT is associated with increased response to pioglitazone in people with Diabetes Mellitus as compared to genotype TT.	G	T	= 0.001	OR	11.483	2.637	50.002
1448615381	rs34231037	sunitinib	Efficacy	yes	Genotype AG is associated with increased clinical benefit to sunitinib as compared to genotype GG.			= 0.047	OR	3.78	1.02	14.06
827816646	rs1390913	lithium	Efficacy	no	Allele A is not associated with response to lithium in people with Bipolar Disorder as compared to allele G.	A	A	= 0.712	OR	1.11	0.69	1.81
827816637	rs2811332	lithium	Efficacy	no	Allele C is not associated with response to lithium in people with Bipolar Disorder as compared to allele G.	C	C	= 0.1658	OR	1.36	0.88	2.09
827816630	rs12693402	lithium	Efficacy	no	Allele C is not associated with response to lithium in people with Bipolar Disorder as compared to allele T.	C	C	= 0.53	OR	1.25	0.58	2.65
827816621	rs11869731	lithium	Efficacy	yes	Genotype CC is associated with increased response to lithium in people with Bipolar Disorder as compared to genotypes CG + GG.	C	C	= 4.7E-4	OR	2.39	1.46	3.89
1447959890	rs4149117	imatinib	Efficacy	yes	Genotypes GG + GT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.			= 0.04	OR	2.17	1.02	4.64
1447959896	rs150929	imatinib	Efficacy	yes	Genotypes GG + GT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.			= 0.012	OR	6.37	1.5	27.18
1447959879	rs7311358	imatinib	Efficacy	yes	Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.			= 0.04	OR	2.17	1.02	4.64
1444699432	rs10465180	clozapine	Efficacy	yes	Genotype CC is associated with decreased response to clozapine in people with Schizophrenia as compared to genotypes CT + TT.			= 0.002	OR	2.15	1.3	3.55
1446534354	rs9332238	warfarin	Dosage	yes	Allele G is associated with increased dose of warfarin as compared to allele A.			= 4.4e-13	OR	6.8	5.0	9.1
1444666251	rs1045642	warfarin	Dosage	yes	Allele A is associated with increased dose of warfarin as compared to allele G.			= 0.04	OR	2.22	0.09	5.11
1446533819	rs749671	warfarin	Dosage	yes	Allele G is associated with increased dose of warfarin as compared to allele A.			= 1.08e-33	OR	20.4	14.3	29.0
1448123009	rs11212617	metformin	Efficacy	no	Allele C is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.			= 0.32	OR	0.86	0.52	1.41
1447680594	rs1061170	photodynamic therapy	Efficacy	no	Genotype TT is not associated with response to photodynamic therapy in people with Macular Degeneration as compared to genotype CC.	C		= 0.4	OR	1.57	0.48	5.2
981349362	rs699947	sildenafil	Efficacy	yes	Genotypes AA + AC are associated with decreased response to sildenafil in men with Erectile Dysfunction as compared to genotype CC.	A	A	= 0.016	OR	2.26	0.92	5.54
981349362	rs699947	sildenafil	Efficacy	yes	Genotypes AA + AC are associated with decreased response to sildenafil in men with Erectile Dysfunction as compared to genotype CC.	A	A	= 0.031	OR	2.81	1.12	7.06
1444698532	rs2760118	methadone	Efficacy	yes	Genotypes CT + TT is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to genotype CC.			= 0.0024	OR	3.16	1.48	6.73
1449154836	rs12917707	cyclosporine	Efficacy	yes	Genotypes GT + TT is associated with increased response to cyclosporine in people with Kidney Transplantation as compared to genotype GG.	T		= 0.05	HR	0.67	0.46	0.97
1450809598	rs5443	sibutramine	Efficacy	yes	Genotype CC is associated with increased response to sibutramine in people with Obesity as compared to genotypes CT + TT.	T	T	= 0.004	OR	6.8	1.8	25.6
1450809598	rs5443	sibutramine	Efficacy	yes	Genotype CC is associated with increased response to sibutramine in people with Obesity as compared to genotypes CT + TT.	T	T	= 0.01	OR	9.6	1.7	53.8
1445402189	rs2072661	varenicline	Efficacy	no	Genotypes AA + AG are not associated with response to varenicline in people with Tobacco Use Disorder as compared to genotype GG.			= 0.81	OR	1.08	0.59	1.98
1449557881	rs1045642	methotrexate	Efficacy	no	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.			= 0.6	OR	0.95	0.8	1.2
655387805	rs1544105	methotrexate	Efficacy	yes	Genotypes CT + TT are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.			= 0.008	OR	3.47	1.19	10.12
1448616501	rs3212227	methotrexate	Other	no	Allele G is not associated with response to methotrexate in people with Psoriasis as compared to allele T.			= 0.007	OR	2.88	1.34	6.16
981419313	rs737865	bupropion	Efficacy	yes	Genotype AA is associated with decreased response to bupropion in smokers as compared to genotypes AG + GG.			= 0.05	OR	0.32	0.1	0.99
981954037	rs1801260	lithium	Efficacy	no	Allele G is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele A.	G		= 0.75	OR	1.07		
981954058	rs2304672	lithium	Efficacy	no	Allele G is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.	G		= 0.1	OR	0.59		
1449713140	rs1800497	bupropion	Efficacy	no	Genotypes AA + AG are not associated with response to bupropion in people with Tobacco Use Disorder as compared to genotype GG.				OR	0.893	0.705	1.132
1449557898	rs17602729	methotrexate	Efficacy	no	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.			= 0.6	OR	1.08	0.8	1.5
1449168211	rs17786394	duloxetine	Efficacy	yes	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.			< 5E-5	OR	0.18		
1449168223	rs17786412	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.18		
769165182	rs25487	fluorouracil	Efficacy	yes	Genotype CC is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype CT.			= 0.01	OR	4.18	1.627	10.741
982036545	rs1801177	fenofibrate	Efficacy	no	Allele A is not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to allele G.				OR	0.74	0.31	1.72
982036545	rs1801177	fenofibrate	Efficacy	no	Allele A is not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to allele G.				OR	1.15	0.46	2.88
1450930674	rs615470	nicotine	Other	no	Allele T is not associated with exposure to nicotine in men as compared to allele C.	T		= 0.260	OR	1.1		
1449558010	rs4982133	methotrexate	Efficacy	no	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.			= 0.2	OR	1.19	0.9	1.6
1448612694	rs1128503	imatinib	Efficacy	yes	Genotype GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.			= 0.022	OR	4.382	1.145	16.774
1448519661	rs1731017	valproic acid	Efficacy	no	Genotypes AA + AG is associated with increased resistance to valproic acid in people with Epilepsy as compared to genotype GG.	A	A	= 0.120	OR	2.795	1.366	5.72
1449167930	rs3889402	duloxetine	Efficacy	yes	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	0.14		
1449557975	rs699517	methotrexate	Efficacy	no	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.			= 0.8	OR	1.03	0.8	1.3
1450928217	rs1805054	risperidone	Efficacy	no	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	T	T	= 1	OR	0.965	0.731	1.273
1450928217	rs1805054	risperidone	Efficacy	no	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	T	T	= 1	OR	1.05	0.761	1.449
1450928217	rs1805054	risperidone	Efficacy	no	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	T	T	= 1	OR	0.973	0.501	1.891
1450928312	rs9606186	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	C	C	= 0.511	OR	0.816	0.615	1.081
1450928312	rs9606186	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	C	C	= 0.511	OR	0.387	0.164	0.91
1450928312	rs9606186	risperidone	Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	C	C	= 1	OR	0.869	0.634	1.192
981861796	rs1800797	peginterferon alfa-2a	Efficacy	yes	Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele A.			= 0.0489	RR	0.78	0.62	1.0
1184166980	rs6822844	rituximab	Efficacy	yes	Genotype GG is associated with increased response to rituximab in people with Lupus Erythematosus, Systemic as compared to genotype GT.	G	G	= 0.016	OR	6.43	1.42	21.07
981502459	rs809736	citalopram	Efficacy	no	Allele G is associated with increased response to citalopram in people with Depressive Disorder, Major as compared to allele A.	G	G	= 3.5	OR	1.52	1.27	1.83
1451104700	rs8065082	metformin	Efficacy	yes	Genotypes CT + TT is associated with increased response to metformin in people with Glucose Intolerance as compared to genotype CC.			= 0.02	HR	0.78	0.64	0.96
981954065	rs228729	lithium	Efficacy	no	Allele T is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.	T		= 0.49	OR	1.14		
981848218	rs4680	venlafaxine	Efficacy	no	Genotype GG is not associated with response to venlafaxine in people with Anxiety Disorders as compared to genotypes AA + AG.	A		= 0.286	OR	1.74		
981848218	rs4680	venlafaxine	Efficacy	no	Genotype GG is not associated with response to venlafaxine in people with Anxiety Disorders as compared to genotypes AA + AG.	A		= 0.501	OR	1.11		
982046735	rs2631372	imatinib	Efficacy	yes	Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.			= 0.043	HR	0.46	0.22	0.97
1184510370	rs2293347	fluorouracil	Efficacy	yes	Genotype CC is associated with decreased response to fluorouracil in people with Stomach Neoplasms as compared to genotypes CT + TT.	C		= 6.32E-8	OR	0.048	0.01	0.38
982043679	rs2740574	amlodipine	Efficacy	no	Genotypes CT + TT are not associated with response to amlodipine in women with Hypertension as compared to genotype CC.			= 0.29	HR	0.67	0.31	1.42
982043670	rs2740574	amlodipine	Efficacy	no	Genotypes CT + TT are not associated with response to amlodipine in people with Hypertension as compared to genotype CC.			= 0.19	HR	1.48	0.82	2.69
982043670	rs2740574	amlodipine	Efficacy	no	Genotypes CT + TT are not associated with response to amlodipine in people with Hypertension as compared to genotype CC.			= 0.44	HR	0.81	0.48	1.38
1183680808	rs1045642	highly active antiretroviral therapy (haart)	Efficacy	yes	Genotypes AA + AG are associated with increased resistance to highly active antiretroviral therapy (haart) in people with HIV Infections as compared to genotype GG.	G		= 0.045	OR	5.01	1.04	24.23
1184510382	rs800292	ranibizumab	Efficacy	no	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.			= 1.0	OR	1.26	0.55	2.85
1184510402	rs1329424	ranibizumab	Efficacy	no	Allele G is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.			= 1.0	OR	0.83	0.46	1.5
1451141783	rs1799971	naltrexone	Efficacy	no	Allele G is not associated with response to naltrexone in people with Alcoholism as compared to allele A.			= 0.33	OR	1.4	0.72	2.74
1451141783	rs1799971	naltrexone	Efficacy	no	Allele G is not associated with response to naltrexone in people with Alcoholism as compared to allele A.			= 0.78	OR	0.92	0.52	1.64
1184467472	rs1801131	methotrexate	Efficacy	no	Genotype GT is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.			= 0.55	OR	0.91	0.65	1.25
1449557938	rs2295553	methotrexate	Efficacy	no	Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.			= 0.1	OR	0.81	0.6	1.02
1447949678	rs2306283	atorvastatin	Efficacy	yes	Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.	G		< 0.05	OR	1.29	0.41	2.08
1446765670	rs1045642	sunitinib	Efficacy	yes	Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.			= 0.005	HR	5.0	1.6	15.2
1446765670	rs1045642	sunitinib	Efficacy	yes	Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.		A	= 0.02	OR	0.2	0.0	0.7
1446765670	rs1045642	sunitinib	Efficacy	yes	Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.	A		= 0.19	HR	1.7	0.8	3.9
1446765670	rs1045642	sunitinib	Efficacy	yes	Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.	A		= 0.21	HR	1.7	0.7	3.8
1447674478	rs1051266	methotrexate	Efficacy	yes	Genotypes CT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	T		= 0.03	OR	2.2	1.1	4.4
1445296596	rs1128503	imatinib	Efficacy	yes	Genotype GG is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.			= 0.036	OR	0.59		
1446754341	rs1128503	sunitinib	Efficacy	no	Genotype AA is not associated with response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.	G	A	= 0.07	HR	1.7	1.0	3.1
1446754341	rs1128503	sunitinib	Efficacy	no	Genotype AA is not associated with response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.	G	A	= 0.09	HR	1.7	0.9	3.2
1446754341	rs1128503	sunitinib	Efficacy	no	Genotype AA is not associated with response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.	G	A	= 0.13	OR	0.5	0.2	1.3
981861804	rs1800796	peginterferon alfa-2a	Efficacy	yes	Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele C.			= 0.0489	RR	0.78	0.62	1.0
1444666926	rs3774261	pioglitazone	Efficacy	no	Genotypes AG + GG are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype AA.	G	A	= 0.856	OR	1.209	0.156	9.352
1444666909	rs2241767	pioglitazone	Efficacy	no	Genotype AA are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotypes AG + GG.	G	A	= 0.826	OR	1.201	0.236	6.12
1444666920	rs3821799	pioglitazone	Efficacy	no	Genotypes CT + TT are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype CC.	C	T	= 0.908	OR	1.131	0.139	9.204
1446896603	rs6265	olanzapine	Efficacy	yes	Genotype CC is associated with increased response to olanzapine in people with Schizophrenia as compared to genotypes CT + TT.			= 0.032	OR	1.9	1.06	3.41
1446896603	rs6265	olanzapine	Efficacy	yes	Genotype CC is associated with increased response to olanzapine in people with Schizophrenia as compared to genotypes CT + TT.			= 0.034	OR	1.98	1.05	3.73
1450928150	rs4633	risperidone	Efficacy	no	Allele T is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.	T	T	> 0.05	OR	3.56	1.24	10.21
1450928225	rs2494732	risperidone	Efficacy	no	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	T	T	= 1	OR	0.923	0.703	1.211
1450928225	rs2494732	risperidone	Efficacy	no	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	T	T	= 1	OR	1.038	0.759	1.419
1450928225	rs2494732	risperidone	Efficacy	no	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	T	T	= 1	OR	0.707	0.358	1.395
1449167906	rs7035619	duloxetine	Efficacy	yes	Allele A is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	4.4		
1447675725	rs462779	cisplatin	Efficacy	yes	Genotypes AG + GG are associated with decreased response to cisplatin in people with Osteosarcoma as compared to genotype AA.	G		= 0.018	OR	2.6	1.18	5.74
1446908196	rs121434568	afatinib	Efficacy	no	Allele G is not associated with response to afatinib in people with Carcinoma, Non-Small-Cell Lung.			= 0.08	HR	0.49	0.22	1.09
1446908196	rs121434568	afatinib	Efficacy	no	Allele G is not associated with response to afatinib in people with Carcinoma, Non-Small-Cell Lung.				HR	1.12	0.94	1.34
1449154515	rs4646	tamoxifen	Efficacy	yes	Genotype AA is associated with decreased response to tamoxifen in women with Breast Neoplasms and Menopause as compared to genotypes AC + CC.	A		= 0.013	HR	3.614	1.308	9.991
1450933226	rs762551	imatinib	Dosage	yes	Genotype CC is associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AC.	C		= 0.001	OR	7.12	2.21	22.9
1450933226	rs762551	imatinib	Dosage	yes	Genotype CC is associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AC.	C		= 0.657	OR	0.81	0.32	2.07
1449164918	rs35511654	methotrexate	Toxicity	no	Allele G is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	G		= 0.77	HR	1.09	0.59	2.01
1446906519	rs776746	sunitinib	Dosage	yes	Allele T is associated with decreased dose of sunitinib in people with Carcinoma, Renal Cell as compared to allele C.			= 0.039	OR	2.04	1.04	4.0
1450933234	rs28656907	imatinib	Dosage	no	Genotype TT is associated with increased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.	T		= 0.040	OR	0.19	0.04	0.93
1450933234	rs28656907	imatinib	Dosage	no	Genotype TT is associated with increased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.	T		= 0.385	OR	0.67	0.27	1.66
1450928170	rs1176713	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.	G	G	= 1	OR	0.983	0.743	1.3
1450928170	rs1176713	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.	G	G	= 1	OR	1.165	0.84	1.615
1450928170	rs1176713	risperidone	Efficacy	no	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.	G	G	= 1	OR	0.819	0.419	1.603
1448634117	rs1427407	hydroxyurea	Efficacy	yes	Allele T is associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele G.	T	T	< 0.01	OR	6.1	1.9	23.1
1448601802	rs2242446	venlafaxine	Efficacy	yes	Genotype CC is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	C		= 0.009	OR	1.67	1.13	2.42
1448995964	rs7234029	adalimumab	Efficacy	no	Allele G is not associated with response to adalimumab in people with Arthritis, Rheumatoid as compared to allele A.	G		= 0.06	OR	0.27	0.07	1.03
1449004334	rs6498169	glatiramer acetate	Efficacy	yes	Allele A is associated with increased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.	A	A	= 0.024	OR	2.86	1.42	5.75
1449005435	rs2032582	imatinib	Efficacy	no	Allele T is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.	G	A	= 0.28	OR	0.57	0.3	1.43
1449166128	rs11559290	methylphenidate	Efficacy	no	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.105	OR	1.62	0.9	2.9
1449168112	rs2419128	duloxetine	Efficacy	yes	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	0.27		
1449166345	rs3761372	methylphenidate	Efficacy	no	Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.			= 0.365	OR	1.31	0.73	2.33
1449167778	rs4858478	duloxetine	Efficacy	yes	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	4.11		
1449168217	rs17786400	duloxetine	Efficacy	yes	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.			< 5E-5	OR	0.18		
1449168246	rs61908404	duloxetine	Efficacy	yes	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.			< 5E-5	OR	0.18		
1449168252	rs61908405	duloxetine	Efficacy	yes	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.			< 5E-5	OR	0.18		
1449168179	rs10771999	duloxetine	Efficacy	yes	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.			< 5E-5	OR	0.13		
1449576323	rs4680	levodopa	Dosage	no	Genotype AA is not associated with dose of levodopa in people with Parkinson Disease as compared to genotype GG.	A		= 0.98	OR	0.8	0.2	2.6
1449576379	rs1799836	levodopa	Dosage	no	Genotype TT is not associated with dose of levodopa in women with Parkinson Disease as compared to genotype CC.	T		= 0.82	OR	1.5	0.3	6.0
1449558016	rs1703794	methotrexate	Efficacy	no	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.			= 0.4	OR	1.12	0.9	1.5
1449164912	rs3393	methotrexate	Toxicity	no	Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	C		= 0.97	HR	0.99	0.58	1.7
1449164974	rs73598374	methotrexate	Toxicity	no	Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	T		= 0.29	HR	0.61	0.24	1.55
1449155451	rs8177374	ustekinumab	Efficacy	yes	Genotypes CT + TT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CC.	T		= 0.0051	OR	9.42	1.96	45.3
1450933253	rs2631367	imatinib	Dosage	no	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	G		= 0.259	OR	0.51	0.16	1.64
1450933253	rs2631367	imatinib	Dosage	no	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	G		= 0.814	OR	0.9	0.38	2.15
1450933458	rs1800810	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	G		= 0.217	OR	0.56	0.23	1.4
1450933458	rs1800810	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	G		= 0.564	OR	0.54	0.07	4.37
1450933577	rs6877011	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	G		= 0.170	OR	2.01	0.74	5.48
1450933577	rs6877011	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	G		= 0.225	OR	4.7	0.39	57.4
1450933294	rs2631370	imatinib	Dosage	no	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.	C		= 0.064	OR	3.08	0.94	10.1
1450933294	rs2631370	imatinib	Dosage	no	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.	C		= 0.185	OR	1.87	0.74	4.74
1450930694	rs3827020	nicotine	Other	no	Allele C is not associated with exposure to nicotine in men as compared to allele T.	C		= 0.340	OR	1.0		
1450928201	rs1800497	risperidone	Efficacy	no	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	A	A	= 1	OR	0.989	0.741	1.321
1450928201	rs1800497	risperidone	Efficacy	no	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	A	A	= 1	OR	0.974	0.709	1.338
1450928201	rs1800497	risperidone	Efficacy	no	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	A	A	= 1	OR	0.845	0.378	1.887
1450930657	rs16969968	nicotine	Other	no	Allele A is not associated with exposure to nicotine in men as compared to allele G.	A		= 0.042	OR	1.3		
1450930622	rs667282	nicotine	Other	no	Allele C is not associated with exposure to nicotine in men as compared to allele T.	C		= 0.008	OR	1.1		
1444843349	rs11231809	methotrexate	Efficacy	yes	Genotypes AT + TT are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.			= 0.031	OR	5.37	1.17	24.71
1450933374	rs683369	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	G		= 0.786	OR	0.89	0.38	2.07
1450933374	rs683369	imatinib	Dosage	no	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	G		= 0.849	OR	0.88	0.23	3.34
1450933561	rs699947	imatinib	Dosage	no	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.	C		= 0.517	OR	1.43	0.48	4.27
1450933561	rs699947	imatinib	Dosage	no	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.	C		= 0.627	OR	1.27	0.48	3.36
1449188815	rs1799971	naltrexone	Efficacy	yes	Allele G is associated with increased response to naltrexone in men with Alcoholism as compared to allele A.			< 0.01	OR	0.75	0.62	0.91
1451104645	rs222749	botulinum toxin type a	Efficacy	yes	Allele A is associated with decreased response to botulinum toxin type a in women with Migraine NOS as compared to allele G.	A	A	= 0.021	OR	3.29	1.28	8.43
769173673	rs4673993	methotrexate	Efficacy	yes	Allele C is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.			= 0.04	OR	1.88	1.03	3.43
1450930602	rs6495307	nicotine	Other	no	Allele T is not associated with exposure to nicotine in men as compared to allele C.	T		= 0.160	OR	1.1		
1448102384	rs4343	sertraline	Efficacy	no	Genotype GG is not associated with response to sertraline in people with Depressive Disorder.	G	G	= 0.999	OR	1.13	0.68	1.88
1296666475	rs61734430	pemetrexed	Efficacy	yes	Genotypes CT + TT is associated with decreased response to pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype CC.	T		= 0.029	OR	3.8	1.15	12.53
827864069	rs1024323	metoprolol	Efficacy	no	Genotype CC is not associated with decreased response to metoprolol in women with hypertensive nephrosclerosis as compared to genotype TT.			= 0.9	HR	1.02	0.65	1.61
981349353	rs1570360	sildenafil	Efficacy	yes	Genotype AA is associated with decreased response to sildenafil in men with Erectile Dysfunction as compared to genotypes AG + GG.	A	A	< 0.001	OR	8.5	2.34	30.92
981349353	rs1570360	sildenafil	Efficacy	yes	Genotype AA is associated with decreased response to sildenafil in men with Erectile Dysfunction as compared to genotypes AG + GG.	A	A	= 0.008	OR	19.93	1.13	350.0
1448995971	rs2233945	etanercept	Efficacy	yes	Allele C is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.	A		= 0.023	OR	0.37	0.16	0.87
827816749	rs2826494	lithium	Efficacy	no	Allele G is associated with response to lithium in people with Bipolar Disorder as compared to allele C.	G	G	= 0.0019	OR	2.07	1.3	3.29
1184747642	rs2231142	sulfasalazine	Other	no	Allele T is not associated with discontinuation of sulfasalazine in people with Arthritis, Rheumatoid as compared to allele G.	T		= 0.69	HR	1.15	0.58	2.26
1184513720	rs529520	buprenorphine	Efficacy	yes	Genotype AA is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype CC.			= 0.006	RR	2.15	1.3	2.29
1184513720	rs529520	buprenorphine	Efficacy	yes	Genotype AA is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype CC.			= 0.025	RR	1.65	1.5	2.06
1184513720	rs529520	buprenorphine	Efficacy	yes	Genotype AA is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype CC.			= 0.05	RR	1.8	1.04	2.02
1296599938	rs1801133	methotrexate	Toxicity	yes	Genotype AA is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.			= 0.004	RR	1.64	1.17	2.3
1296599938	rs1801133	methotrexate	Toxicity	yes	Genotype AA is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.			= 0.005	RR	1.6	1.15	2.22
1296599938	rs1801133	methotrexate	Toxicity	yes	Genotype AA is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.			= 0.35	RR	2.26	0.4	12.68
1449147078	rs1801133	fluorouracil	Efficacy	yes	Genotypes AA + AG is associated with increased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	A		= 0.006	OR	3.8	1.45	9.92
1448617505	rs3745274	efavirenz	Efficacy	yes	Genotypes GT + TT are associated with decreased resistance to efavirenz in people with HIV Infections as compared to genotype GG.	T	T	= 0.03	OR	0.7	0.5	0.97
